CNS Delivery of mRNA and Methods of Use
Lipid-based nanoparticles facilitate the delivery of mRNA across nerve cell membranes in the CNS, addressing the challenge of treating CNS diseases by efficiently delivering therapeutic proteins to neurons, as demonstrated in treating spinal muscular atrophy.
Patent Information
- Application Number
- JP2022103427
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2014-07-02
- Filing Date
- 2022-06-28
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2034-10-22
AI Technical Summary
The blood-brain barrier poses a significant obstacle to delivering effective treatments for CNS diseases, particularly those caused by protein deficiencies, as existing methods struggle to permeate and deliver therapeutic agents, such as mRNA, to nerve cells in the central nervous system.
A method involving lipid- or polymer-based nanoparticles is used to deliver mRNA encoding therapeutic proteins directly into neurons and other cells in the CNS, utilizing intraspinal administration to cross nerve cell membranes efficiently, with compositions containing cationic or non-cationic lipids, cholesterol-based lipids, and PEG-modified lipids.
This approach allows for intracellular delivery of mRNA to neurons in the brain and spinal cord, potentially treating diseases like spinal muscular atrophy by encoding and expressing essential proteins, such as the survival motor neuron protein, thereby overcoming the barriers imposed by the blood-brain barrier.
Smart Images

Figure 0007586858000025 
Figure 0007586858000026 
Figure 0007586858000027
Abstract
Description
[Technical field]
[0001] (Related Applications) This application is a joint venture of US62 / 020,161 (filed July 2, 2014) and US61 / 894, No. 246, filed October 22, 2013, the disclosures of which are incorporated herein by reference. It is incorporated by Sequence Listing
[0002] This specification is incorporated by reference in its sequence listing ("2006685-0690_SL.t Submit electronically in a .txt file named ".xt." The file was created on October 22, 2014 and is 19,590 bytes in size. The entire contents of this sequence listing are incorporated by reference. [Background technology]
[0003] Effective treatment is the result of a defect, abnormal expression, or dysregulation of a protein in nerve cells and for the treatment of CNS disorders, including those caused directly or indirectly by There is a major need for effective treatment of CNS diseases. Many diseases are caused by the separation and segregation of biological tissues of the CNS by the blood-brain barrier (BBB), There are many obstacles.
[0004] For example, spinal muscular atrophy is a CNS disease caused by a protein deficiency. The researchers identified the survival motor neuron (SMN) genes, SMN-1 and SMN-2, respectively. The gene has a functional copy of the , which is nearly identical in sequence. Patients who have been treated with serotonin-releasing hormone (SMN-1) are generally unable to express the full-length SMN-1 protein and have The expression of 2 is dependent on low levels of the full-length 2, which is expressed only in motor neurons in the brain. However, this is not enough to prevent the deaths of the In recent years, messenger RNA (mRNA) therapy has become increasingly popular for the treatment of various diseases, particularly one or more It is becoming an increasingly important option in the treatment of several protein deficiency-related diseases. While showing promise for non-neurological diseases, those skilled in the art are aware that liposomes are unable to cross the BBB. Given the inability to deliver mRNA into neurons and the unique challenges involved, The unique and complex membrane composition of human CNS cells makes it possible to develop methods to treat CNS disorders. (Svennerhol et.al., Biochimica et Bi ophysica Acta, 1992, 1128:1-7, and Karthigasa n et.al., Journal of Neurochemistry, 1994, 62:1203-1213). [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Svennerhol et.al., Biochimica et Biophysica Acta, 1992, 1128:1-7 [Non-Patent Document 2] Karthigasan et.al.,Journal of Neurochemistry,1994,62:1203-1213 Summary of the Invention [Means for solving the problem]
[0006] The present invention relates in particular to the delivery of mRNA encoding a therapeutic protein to neurons of the CNS and other The present invention provides improved methods and compositions for efficient delivery to cell types. In a study, mRNA-loaded lipid or polymer-based nanoparticles were directly delivered to the CNS It is administered into the brain (e.g., by intraspinal administration) and effectively crosses the neuronal membrane to reach the brain. and / or in neurons in the spinal cord. Prior to this invention, it was not known whether neuronal membranes were the same as those of non-neuronal cells. It has been reported that the lipid composition of the serovar Sv is unique and complex, unlike that of the serovar Sv. ennerhol et.al., Biochimica et Biophysica Acta, 1992, 1128:1-7, and Karthigasan et.al. ,Journal of Neurochemistry,1994,62:1203- 1213) Therefore, it was thought that the neuronal membrane was difficult to cross. Even liposomes that are effective for delivery to the vesicles are not as effective at crossing neuronal membranes. This was not expected. It is located deep in the center of the brain and spinal column and has difficulty acting on motor neurons. However, the lipid or polymer-based nanoparticles described herein can effectively deliver mRNA It was truly surprising that it was possible to deliver the provide an improved and effective method for CNS delivery of mRNA and This holds promise as an effective mRNA therapy for treating S disease.
[0007] Thus, in one embodiment, the present invention provides a method for delivering mRNA to the central nervous system (CNS). In some embodiments, the method according to the present invention further comprises administering the composition to a subject in need thereof. and / or in neurons in the spinal cord, resulting in intracellular delivery of mRNA. The present invention relates to a method for delivering a composition comprising an mRNA encoding a protein encapsulated in a vesicle. and intrathecal administration to a subject, wherein the liposomes are cationic or non-cationic. These include ionic lipids, cholesterol-based lipids, and PEG-modified lipids.
[0008] In some embodiments, the mRNA is delivered to neurons located in the brain. In some embodiments, the mRNA is delivered to neurons located in the spinal cord. In some embodiments, the mRNA is delivered to a motor neuron. In an embodiment, the mRNA is delivered to upper motor neurons and / or lower motor neurons. In some embodiments, the motor neurons are delivered to the anterior horn of the spinal cord and / or Located in the dorsal root ganglion.
[0009] In some embodiments, suitable liposomes contain one or more cationic lipids. , one or more neutral lipids, one or more cholesterol-based lipids, and one or more or multiple types of PEG-modified lipids.
[0010] In some embodiments, suitable cationic lipids include C12-200, MC3, D LinDMA, DLinkC2DMA, cKK-E12, ICE (imidazole type), H GT5000, HGT5001, DODAC, DDAB, DMRIE, DOSPA, DO GS, DODAP, DODMA, and DMDMA, DODAC, DLenDMA, DMR IE, CLinDMA, CpLinDMA, DMOBA, DOcarbDAP, DLin DAP, DLincarbDAP, DLinCDAP, KLin-K-DMA, DLin -K-XTC2-DMA, HGT4003. In an embodiment, the one or more cationic lipids include C12-200. In certain embodiments, the cationic lipid comprises DLinK22DMA.
[0011] In certain embodiments, a cationic lipid suitable for the present invention has the structure of formula I-c1-a: death, [ka] or a pharma- ceutically acceptable salt thereof, wherein: Each R 2 are independently hydrogen or C 1-3 is an alkyl group of the formula each q is independently 2 to 6; Each R' is independently hydrogen or C 1-3 is an alkyl group of the formula And each R L is independently C 8-12 is an alkyl group.
[0012] In certain embodiments, a suitable cationic lipid is cKK-E12: [ka] It is.
[0013] In some embodiments, a suitable non-cationic lipid is distearoylphosphatidylcholine. dioleoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoyl dioleoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DO PG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidyl DOPE, palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE) , dioleoylphosphatidylethanolamine-4-(N-maleimidomethyl)-cyclohexyl Dodecane-l-carboxylate (DOPE-mal), dipalmitoyl phosphatidylcholine dimyristoyl phosphoethanolamine (DPPE), dimyristoyl phosphoethanolamine (DMPE) , Distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomer 16-O-dimethyl polyethylene, 18-1-trans polyethylene , l-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE), phosphatidyl lipids, or mixtures thereof.
[0014] In some embodiments, a suitable non-cationic lipid is a phosphatidyl lipid. In some embodiments, a suitable phosphatidyl lipid is a sphingolipid. In some particular embodiments, the preferred sphingolipid is sphingomyelin. .
[0015] In some embodiments, one or more cholesterol-based lipids suitable for the present invention The substances include cholesterol, pegylated cholesterol, and / or DC-Chol(N ,N-Dimethyl-N-ethylcarboxamidocholesterol),1,4-bis(3-N- oleylamino-propyl)piperazine.
[0016] In some embodiments, the one or more PEG-modified lipids suitable for the present invention include: C6~C 20Covalently linked to lipids with alkyl chains of 5 kDa or more in length In some embodiments, a suitable PEG-modified carboxylate may include a poly(ethylene) glycol chain. The decorative lipid was N-octanoyl-sphingosine-1-[succinyl(methoxypolyethylene In some embodiments, the ceramide is a derivatized ceramide such as glycerol (methacrylamide glycol)-2000. Suitable PEG-modified or PEGylated lipids include PEGylated cholesterol or or dimyristoylglycerol (DMG)-PEG-2K. In the above, the one or more PEG-modified lipids are DMG-PEG, C8-PEG, D From the group consisting of OG PEG, ceramide PEG, DSPE-PEG, and mixtures thereof In some embodiments, the one or more PEG-modified lipids are selected from About 1 to 10% (e.g., about 1 to 8%, about 1 to 6%, or about 1 to 5%) by molar ratio of the lipid composition In some embodiments, the one or more PEG-modified lipids comprise Constituting about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10% by molar ratio of the total lipid composition In some particular embodiments, the PEG-modified lipid comprises a minor molar proportion of the total lipid composition. constitute at least 5%.
[0017] In some embodiments, suitable liposomes include C12-200, sphingomyelin C12-200, DOPE, cholesterol, and DMG PEG; C12-200, DOPE, cholesterol Sterol, DMG-PEG2K; cKK-E12, DOPE, cholesterol, and and DMG-PEG2K;cKK-E12, sphingomyelin, DOPE, cholesterol HGT5001, DOPE, cholesterol, and DMG -PEG2K; HGT4003, DOPE, cholesterol, and DMG-PEG2K; DLinKC2DMA, DOPE, cholesterol and DMG-PEG2K; ICE, D OPE, cholesterol and DMG-PEG2K, or DODMA, DOPE, cholesterol Sterol and DMG-PEG2K; DODMA, sphingomyelin, DOPE, cholesterol A mixture selected from sterols, DMG-PEG2K, and / or mixtures thereof. Includes things.
[0018] In some embodiments, suitable liposomes include commercially available enhancers. In some embodiments, the liposome comprises a biodegradable lipid. In some embodiments, the liposome comprises an ionic lipid. Contains possible lipids.
[0019] In some embodiments, suitable liposomes are about 250 nm, 200 nm, 150 nm, nm, 125nm, 110nm, 100nm, 95nm, 90nm, 85nm, 80nm , 75nm, 70nm, 65nm, 60nm, 55nm, or sizes below 50nm In some embodiments, suitable liposomes have a diameter of about 40-100 nm (e.g., about 40-90 nm, about 40-80 nm, about 40-70 nm, or about 40-60 nm) As used herein, the size of a liposome is determined by the size of the liposome particle. Determine the length of the largest diameter of the seed.
[0020] In some embodiments, the mRNA is about 0.5 kb, 1 kb, 1.5 kb, 2 kb, , 2.5kb, 3kb, 3.5kb, 4kb, 4.5kb, or longer than 5kb Yes.
[0021] In some embodiments, the therapeutic protein encoded by the mRNA is In some embodiments, the therapeutic is an itosolic protein. In some embodiments, the protein is encoded by an mRNA. The therapeutic protein administered is an enzyme. In some embodiments, the enzyme is a lysosomal protein. In some embodiments, the therapeutic protein encoded by the mRNA is a In some embodiments, the mRNA is a protein associated with a CNS disease. Therapeutic proteins encoded by GFP normally function in neurons in the brain and / or spinal cord. In some embodiments, the therapeutic protein encoded by the mRNA is It functions in motor neurons in the medulla.
[0022] In some embodiments, the therapeutic protein encoded by the mRNA is a survival motility agent. In some embodiments, the therapeutic agent encoded by the mRNA is a neuronal protein. The therapeutic protein is survival motor neuron-1 protein. In some embodiments, The therapeutic protein encoded by the mRNA is survival motor neuron protein-1. In some embodiments, the polypeptide is a splice isoform, fragment, or truncated variant of the polypeptide. In some embodiments, the SMN-1 protein comprises the amino acid sequence of SEQ ID NO:2. In one embodiment, the mRNA encoding the SMN-1 protein has the nucleic acid sequence of SEQ ID NO:1. In some embodiments, the mRNA encoding the SMN-1 protein is The donor-optimized sequence is SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:10, or SEQ ID NO: Includes 11.
[0023] In some embodiments, the mRNA suitable for the present invention includes a 5'UTR sequence. In some embodiments, the 5'UTR sequence comprises SEQ ID NO:7. In some embodiments, the mRNA comprises a 3'UTR. The sequence comprises SEQ ID NO: 8 or SEQ ID NO: 9. In some embodiments, the mRNA is In some embodiments, suitable cap structures include cap 0, cap In some embodiments, the preferred structure is selected from the group consisting of cap 1, cap 2, and cap 3. The cap structure is either an anti-reverse cap analog (ARCA) or a modified AR I am a CA.
[0024] In some embodiments, the mRNA encoding the therapeutic protein is one or more In some embodiments, one or more The nucleotides of interest are pseudouridine, 2-aminoadenosine, 2-thiouridine, and iodouracil. adenosine, pyrrolo-pyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 proline C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromo Uridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7- Deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine , O(6)-methylguanine, N-1-methylpseudouridine, 2-thiocytidine and and mixtures thereof.
[0025] In some embodiments, the mRNA encoding the therapeutic protein is modified not present.
[0026] In some embodiments, intracellular delivery of the mRNA involves the delivery of the mRNA-encoded protein. In some embodiments, the encoded protein is expressed by a nuclease. In some embodiments, the encoded protein is expressed in the cytosol of the host. The protein is expressed and then secreted extracellularly from the neuron.
[0027] In some embodiments, the mRNA is administered at a concentration of about 0.01 to 10.0 mg / kg of body weight. g, for example, about 0.01 to 9.0 mg, 0.01 to 8.0 mg, 0.0 1~7.0mg, 0.01~6.0mg, 0.01~5.0mg, 0.01~4.0mg , 0.01~3.0mg, 0.01~2.5mg, 0.01~2.0mg, 0.01~1 .5mg, 0.01~1.0mg, 0.01-0.5mg, 0.01-0.25mg, 0 .01~0.1mg, 0.1~10.0mg, 0.1~5.0mg, 0.1~4.0mg , 0.1~3.0mg, 0.1~2.0mg, 0.1~1.0mg, 0.1~0.5mg In some embodiments, the mRNA is administered at a dose ranging from 100 mg / kg body weight to 100 mg / kg body weight. Approximately 10.0mg, 9.0mg, 8.0mg, 7.0mg, 6.0mg, 5.0mg, 4 .5mg, 4.0mg, 3.5mg, 3.0mg, 2.5mg, 2.0mg, 1.5mg , 1.0mg, 0.8mg, 0.6mg, 0.5mg, 0.4mg, 0.3mg, 0.2 mg, 0.1 mg, 0.05 mg, 0.04 mg, 0.03 mg, 0.02 mg, or Doses of less than 0.01 mg are administered.
[0028] In some embodiments, the mRNA is capable of being administered to a subject without eliciting substantial toxicity or an immune response. It will be delivered promptly.
[0029] In another embodiment, the methods described herein can be used to deliver a deletion to the CNS. By delivering messenger RNA (mRNA) that codes for a protein that is involved in the central nervous system, To treat a disease, disorder, or abnormality related to a deficiency of a protein in the central nervous system (CNS) In some embodiments, the CNS disease, disorder, or condition is a tumor In some embodiments, the disease, disorder, or condition is a result of a deficiency of a protein. The defect is the result of a protein deficiency in the motor neurons.
[0030] In particular, the present invention provides methods and compositions for treating spinal muscular atrophy.
[0031] In one embodiment, the present invention relates to a method for the delivery of a gene to the CNS using the methods described herein. Messenger RNA (mRNA) encoding the spared motor neuron (SMN) protein The present invention provides a method for treating spinal muscular atrophy by delivering
[0032] In another aspect, the present invention provides a composition for treating spinal muscular atrophy. , encoding survival motor neuron (SMN) protein, encapsulated in liposomes. RNA, wherein the mRNA is SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:10, or comprises SEQ ID NO: 11 (corresponding to codon-optimized human SMN mRNA), and Further, the liposomes are composed of cationic or non-cationic lipids, cholesterol, and the like. These include PEG-based lipids and PEG-modified lipids.
[0033] In a related aspect, the present invention provides a composition for treating spinal muscular atrophy. and encoding the survival motor neuron (SMN) protein, encapsulated in liposomes. mRNA, wherein the liposome comprises a cationic lipid of formula I-c1-a. , [ka] or a pharma- ceutically acceptable salt thereof, wherein: Each R 2 are independently hydrogen or C 1-3 is an alkyl group of the formula each q is independently 2 to 6; Each R' is independently hydrogen or C 1-3 is an alkyl group of the formula And each R L is independently C 8-12 is an alkyl group.
[0034] In some embodiments, a suitable cationic lipid is cKK-E12: [ka] It is.
[0035] In some embodiments, the present invention provides a composition for treating spinal muscular atrophy. The mice were provided with a liposome-encapsulated gene encoding the survival motor neuron (SMN) protein. wherein the liposome comprises C12-200, sphingomyelin, DOPE, cholesterol, and DMGPEG ; C12-200, DOPE, cholesterol, and DMG-PEG2K; cKK-E12, DOPE, cholesterol, and DMG-PEG2K; cKK-E12, sphingomyelin, DOPE, cholesterol, and DMG-PE G2K; HGT5001, DOPE, cholesterol, and DMG-PEG2K; HGT4003, DOPE, cholesterol, and DMG-PEG2K; DLinKC2DMA, DOPE, cholesterol, and DMG-PEG2K; ICE, DOPE, cholesterol, and DMG-PEG2K; DODMA, DOPE, cholesterol, and DMG-PEG2K; or DODMA, sphingomyelin, DOPE, cholesterol, and DMG-PEG2 K.
[0036] Other features, objects, and advantages of the invention are set forth in the following detailed description, drawings, and claims. However, the detailed description, drawings, and claims provide a basis for the present invention. While embodiments are illustrated, it should be understood that they are given by way of illustration only and not limitation. Various changes and modifications within the scope of the present invention will become apparent to those skilled in the art. In an embodiment of the present invention, for example, the following items are provided: (Item 1) 1. A method for delivering messenger RNA (mRNA) to the central nervous system (CNS), comprising: administering intrathecally to a subject in need thereof a composition comprising an mRNA encoding a protein encapsulated in a liposome, such that administration of the composition results in intracellular delivery of the mRNA in neurons in the brain and / or spinal cord; A method wherein the liposome comprises a cationic or non-cationic lipid, a cholesterol-based lipid and a PEG-modified lipid. (Item 2) 2. The method of claim 1, wherein the neurons in the brain and / or spinal cord comprise motor neurons in the spinal cord. (Item 3) 2. The method of claim 1, wherein the neurons in the brain and / or spinal cord are selected from the group consisting of oligodendrocytes, oligodendroglial cells, astrocytes, glial cells, and combinations thereof. (Item 4) 3. The method of claim 1 or 2, wherein the neurons in the brain and / or spinal cord comprise spinal cord anterior horn cells and dorsal root ganglia. (Item 5) The method of any one of the preceding items, wherein the liposome comprises one or more cationic lipids, one or more neutral lipids, one or more cholesterol-based lipids, and one or more PEG-modified lipids. (Item 6) 6. The method of claim 5, wherein the one or more cationic lipids are selected from the group consisting of C12-200, MC3, DLinDMA, DLinkC2DMA, cKK-E12, ICE (imidazole-based), HGT5000, HGT5001, DODAC, DDAB, DMRIE, DOSPA, DOGS, DODAP, DODMA and DMDMA, DODAC, DLenDMA, DMRIE, CLinDMA, CpLinDMA, DMOBA, DOcarbDAP, DLinDAP, DLincarbDAP, DLinCDAP, KLin-K-DMA, DLin-K-XTC2-DMA, HGT4003, and combinations thereof. (Item 7) The method according to claim 6, wherein the one or more cationic lipids include C12-200. 7. The method of claim 6, wherein the one or more cationic lipids comprise DLinkC2DMA. (Item 9) The cationic lipid is cKK-E12: [ka] 7. The method according to item 6, wherein (Item 10) The one or more non-cationic lipids may be selected from the group consisting of DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DOPE (1,2-dioleyl-sn-glycero-3-phosphoethanolamine), DOPC (1,2-dioleyl-sn-glycero-3-phosphatidylcholine), DPPE (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine), amine), DMPE (1,2-dimyristoyl-sn-glycero-3-ethanolamine phosphate), DOPG (,2-dioleoyl-sn-glycero-3-phosphate-(1'-rac-glycerol)), sphingomyelin, ceramide, cephalin, cerebroside, diacylglycerol, POPC, DOPG, DPPG, POPC, POPE, DSPE, SOPE, sphingomyelin. (Item 11) 11. The method of claim 10, wherein the one or more non-cationic lipids comprise sphingomyelin. (Item 12) The method of any one of the preceding items, wherein the one or more PEG-modified lipids are selected from the group consisting of DMG-PEG, C8-PEG, DOG PEG, ceramide PEG, DSPE-PEG, and combinations thereof. (Item 13) Item 13. The method according to item 12, wherein the one or more PEG-modified lipids constitute about 1 to 10% by molar ratio in the total lipid composition. (Item 14) 13. The method of claim 12, wherein the one or more PEG-modified lipids constitute about 5% by molar ratio in the total lipid composition. (Item 15) 13. The method of any one of the preceding items, wherein the one or more cholesterol-based lipids are selected from cholesterol, or PEGylated cholesterol. (Item 16) The liposome is C12-200, sphingomyelin, DOPE, cholesterol, and DMGPEG; C12-200, DOPE, cholesterol, and DMG-PEG2K; cKK-E12, DOPE, cholesterol, and DMG-PEG2K; cKK-E12, sphingomyelin, DOPE, cholesterol, and DMG-PEG2K; HGT5001, DOPE, cholesterol, and DMG-PEG2K; HGT4003, DOPE, cholesterol, and DMG-PEG2K; DLinKC2DMA, DOPE, cholesterol, and DMG-PEG2K; ICE, DOPE, cholesterol, and DMG-PEG2K; DODMA, DOPE, cholesterol, and DMG-PEG2K; or DODMA, sphingomyelin, DOPE, cholesterol, and DMG-PEG2K, The method of any one of the preceding items, including a combination selected from: (Item 17) 13. The method of any one of the preceding items, wherein the liposomes have a size in the range of about 40 to 100 nm. (Item 18) 10. The method of any one of the preceding items, wherein the mRNA has a length of about 0.5 kb, 1 kb, 1.5 kb, 2 kb, 2.5 kb, 3 kb, 3.5 kb, 4 kb, 4.5 kb, or 5 kb or more. (Item 19) 13. The method of any one of the preceding items, wherein the protein encoded by the mRNA normally functions in the neuron in the brain and / or spinal cord. (Item 20) 13. The method of any one of the preceding items, wherein the protein encoded by the mRNA normally functions in a motor neuron in the spinal cord. (Item 21) 11. The method of any one of the preceding items, wherein the protein encoded by the mRNA is survival motor neuron (SMN) protein. (Item 22) 13. The method of any one of the preceding items, wherein the mRNA is codon optimized. (Item 23) 23. The method of claim 22, wherein the codon-optimized mRNA comprises SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:10, or SEQ ID NO:11. (Item 24) 23. The method of claim 22, wherein the codon-optimized mRNA comprises SEQ ID NO: 3 or SEQ ID NO: 4. (Item 25) 25. The method of claim 24, wherein the mRNA comprises the 5'UTR sequence of SEQ ID NO:7. (Item 26) 25. The method of claim 24, wherein the mRNA comprises the 3'UTR sequence of SEQ ID NO:8 or SEQ ID NO:9. (Item 27) 2. The method of any one of the preceding items, wherein the mRNA comprises a cap structure. (Item 28) 28. The method of claim 27, wherein the cap structure is selected from a cap0, cap1, or cap2 structure. (Item 29) 28. The method of claim 27, wherein the cap structure is an anti-reverse cap analog (ARCA) or a modified ARCA. (Item 30) 21. The method according to any one of items 1 to 20, wherein the protein encoded by the mRNA is an enzyme. (Item 31) 31. The method of claim 30, wherein the enzyme is a lysosomal enzyme. (Item 32) 13. The method of any one of the preceding items, wherein intracellular delivery of the mRNA results in intracellular expression of the protein encoded by the mRNA in the cytosol of the neuron. (Item 33) 13. The method of any one of the preceding items, wherein intracellular delivery of the mRNA results in intracellular expression of the protein encoded by the mRNA and, following expression, extracellular secretion from the neuron. (Item 34) 13. The method of any one of the preceding items, wherein the mRNA comprises one or more modified nucleotides. (Item 35) 35. The method of claim 34, wherein the one or more modified nucleotides comprise pseudouridine, 2-aminoadenosine, 2-thiouridine, inosine, pyrrolo-pyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, N-1-methylpseudouridine, and / or 2-thiocytidine. (Item 36) 34. The method according to any one of items 1 to 33, wherein the mRNA is unmodified. (Item 37) 13. The method of any one of the preceding items, wherein the mRNA is delivered in an amount ranging from about 0.01 mg to about 10 mg per kg of body weight. (Item 38) The method of any one of the preceding items, wherein the mRNA is delivered without eliciting substantial toxicity or immune response. (Item 39) 13. The method of any one of the preceding items, wherein the subject is deficient in the protein encoded by the mRNA in the CNS. (Item 40) A method for treating a disease, disorder, or abnormality in the central nervous system (CNS) associated with a deficiency of a protein, comprising delivering messenger RNA (mRNA) encoding the deficient protein to the CNS using a method according to any one of the preceding items. (Item 41) 1. A method of treating spinal muscular atrophy, comprising: administering intrathecally to a subject in need of treatment a composition comprising mRNA encoding a survival motor neuron (SMN) protein encapsulated in a liposome, such that administration of the composition results in intracellular delivery of the mRNA in neurons in the brain and / or spinal cord; A method wherein the liposome comprises a cationic or non-cationic lipid, a cholesterol-based lipid and a PEG-modified lipid. (Item 42) 42. The method of claim 41, wherein the neurons in the brain and / or spinal cord comprise motor neurons in the spinal cord. (Item 43) 43. The method of claim 41 or 42, wherein the neurons in the brain and / or spinal cord comprise spinal anterior horn cells and dorsal root ganglia. (Item 44) 44. The method according to any one of items 41 to 43, wherein the codon-optimized mRNA comprises SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 10, or SEQ ID NO: 11. (Item 45) 44. The method according to any one of items 41 to 43, wherein the codon-optimized mRNA comprises SEQ ID NO: 3 or SEQ ID NO: 4. (Item 46) 46. The method of claim 45, wherein the mRNA comprises the 5'UTR sequence of SEQ ID NO:7. (Item 47) 46. The method of claim 45, wherein the mRNA comprises the 3'UTR sequence of SEQ ID NO:8 or SEQ ID NO:9. (Item 48) 48. The method according to any one of items 41 to 47, wherein the one or more non-cationic lipids comprise sphingomyelin. (Item 49) The liposome is C12-200, sphingomyelin, DOPE, cholesterol, and DMG PEG; C12-200, DOPE, cholesterol, and DMG-PEG2K; cKK-E12, DOPE, cholesterol, and DMG-PEG2K; cKK-E12, sphingomyelin, DOPE, cholesterol, and DMG-PEG2K; HGT5001, DOPE, cholesterol, and DMG-PEG2K; HGT4003, DOPE, cholesterol, and DMG-PEG2K; DLinKC2DMA, DOPE, cholesterol, and DMG-PEG2K; ICE, DOPE, cholesterol, and DMG-PEG2K; DODMA, DOPE, cholesterol, and DMG-PEG2K; or DODMA, sphingomyelin, DOPE, cholesterol, and DMG-PEG2K, 49. The method according to any one of items 41 to 48, comprising a combination selected from the following: (Item 50) A composition for the treatment of spinal muscular atrophy, comprising: an mRNA encoding said survival motor neuron (SMN) protein encapsulated within a liposome, wherein said codon-optimized mRNA comprises SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:10, or SEQ ID NO:11; Further, the composition wherein the liposome comprises a cationic or non-cationic lipid, a cholesterol-based lipid, and a PEG-modified lipid. (Item 51) A composition for the treatment of spinal muscular atrophy, comprising: A composition comprising an mRNA encoding said survival motor neuron (SMN) protein encapsulated within a liposome, wherein said liposome comprises a cationic lipid of formula I-c1-a, [ka] or a pharma- ceutically acceptable salt thereof, wherein: Each R 2 are independently hydrogen or C 1-3 is an alkyl group of the formula each q is independently 2 to 6; Each R' is independently hydrogen or C 1-3 is an alkyl group of the formula and each R L is independently C 8-12 is an alkyl group. (Item 52) The cationic lipid is cKK-E12: [ka] Item 45. The method according to item 44, wherein (Item 53) A composition for treating spinal muscular atrophy, comprising: and an mRNA encoding said survival motor neuron (SMN) protein encapsulated within a liposome, wherein said liposome comprises: C12-200, sphingomyelin, DOPE, cholesterol, and DMG PEG; C12-200, DOPE, cholesterol, and DMG-PEG2K; cKK-E12, DOPE, cholesterol, and DMG-PEG2K; cKK-E12, sphingomyelin, DOPE, cholesterol, and DMG-PEG2K; HGT5001, DOPE, cholesterol, and DMG-PEG2K; HGT4003, DOPE, cholesterol, and DMG-PEG2K; DLinKC2DMA, DOPE, cholesterol, and DMG-PEG2K; ICE, DOPE, cholesterol, and DMG-PEG2K; DODMA, DOPE, cholesterol, and DMG-PEG2K; or DODMA, sphingomyelin, DOPE, cholesterol, and DMG-PEG2K, A composition comprising a combination selected from: [Brief description of the drawings]
[0037] The drawings are only illustrative and are not limiting of the invention.
[0038] [Figure 1] Figure 1 shows detection of human SMN-1 protein from exogenous hSMN-1 mRNA transfected into BHK-21 cells by Western blot using various antibodies specific for human SMN: (A) anti-SMN 4F11 antibody at 1:1,000 dilution, (B) Pierce PA5-27309 a-SMN antibody at 1:10,000 dilution, and (C) LSBio C138149 a-SMN antibody at 1:10,000 dilution. [Figure 2A] Figures 2A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 1. [Figure 2B] Figures 2A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 1. [Figure 2C] Figures 2A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 1. [Figure 3A] Figures 3A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 2. [Figure 3B] Figures 3A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 2. [Figure 3C]Figures 3A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 2. [Figure 4A] Figures 4A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 3. [Figure 4B] Figures 4A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 3. [Figure 4C] Figures 4A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 3. [Figure 5A] 5A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 4. [Figure 5B] 5A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 4. [Figure 5C] 5A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 4. [Figure 6A]6A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 5. [Figure 6B] 6A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 5. [Figure 6C] 6A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 5. [Figure 7A] 7A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 6. [Figure 7B] 7A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 6. [Figure 7C] 7A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 6. [Figure 8A] 8A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 7. [Figure 8B]8A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 7. [Figure 8C] 8A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery with liposomal formulation 7. [Figure 9A] 9A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 8. [Figure 9B] 9A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 8. [Figure 9C] 9A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 8. [Figure 10A] 10A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 9. [Figure 10B] 10A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 9. [Figure 10C]10A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 9. [Figure 11A] 11A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 10. [Figure 11B] 11A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 10. [Figure 11C] 11A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 10. [Figure 12A] 12A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 11. [Figure 12B] 12A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 11. [Figure 12C] 12A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 11. [Figure 13A]13A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 12. [Figure 13B] 13A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 12. [Figure 13C] 13A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 12. [Figure 14A] 14A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 13. [Figure 14B] 14A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 13. [Figure 14C] 14A-C show multiplexed nucleic acid in situ detection of human survival motor neuron (hSMN-1) mRNA in (A) cervical, (B) thoracic, and (C) lumbar spinal cord tissues 24 hours after intrathecal delivery using liposomal formulation 13. [Figure 15] Figure 15 shows in situ detection of human survival motor neuron (hSMN-1) mRNA in spinal cord tissue 24 hours after intrathecal delivery of vehicle control. Images are shown at 5x magnification. [Figure 16] Figure 16 shows in situ detection of human survival motor neuron (hSMN-1) mRNA in spinal cord tissue 24 hours after intrathecal delivery of vehicle control. Images are shown at 10x magnification. [Figure 17] FIG. 17 shows in situ detection of UbC mRNA in spinal cord tissue 24 hours after vehicle control intrathecal delivery. [Figure 18] Figure 18 shows in situ detection of human survival motor neuron (hSMN-1) mRNA in spinal cord tissue 24 hours after intrathecal delivery of vehicle control. Images are shown at 5x magnification. [Figure 19] Figure 19 shows in situ detection of human survival motor neuron (hSMN-1) mRNA in spinal cord tissue 24 hours after intrathecal delivery. Images are shown at 5x magnification. [Figure 20] Figure 20 shows in situ detection of human survival motor neuron (hSMN-1) mRNA in spinal cord tissue 24 hours after intrathecal delivery. Images are shown at 10x magnification. [Figure 21] Figure 21 shows in situ detection of human survival motor neuron (hSMN-1) mRNA in spinal cord tissue 24 hours after intrathecal delivery. Images are shown at 10x and 20x magnification. [Figure 22] Figure 22 shows positive detection of human SMN-1 protein produced in the spinal cord of rats 24 hours after intraspinal administration of lipid nanoparticles loaded with human SMN-1 mRNA. Anti-human SMN 4F11 antibody was used at a dilution of 1:2500. Panel A represents spinal cord tissue from a treated rat, and panel B represents spinal cord tissue from an untreated rat. [Figure 23A] Figures 23A-C show in situ detection of human survival motor neuron (hSMN-1) mRNA in brain tissue 30 minutes after intrathecal delivery. In situ detection in brain (A) shows strong signal observed in both grey and white matter of the brain. Two regions of brain (B) section 1 and brain (C) section 2 have been enlarged for more detailed analysis. [Figure 23B]Figures 23A-C show in situ detection of human survival motor neuron (hSMN-1) mRNA in brain tissue 30 minutes after intrathecal delivery. In situ detection in brain (A) shows strong signal observed in both grey and white matter of the brain. Two regions of brain (B) section 1 and brain (C) section 2 have been enlarged for more detailed analysis. [Figure 23C] Figures 23A-C show in situ detection of human survival motor neuron (hSMN-1) mRNA in brain tissue 30 minutes after intrathecal delivery. In situ detection in brain (A) shows strong signal observed in both grey and white matter of the brain. Two regions of brain (B) section 1 and brain (C) section 2 have been enlarged for more detailed analysis. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0039] definition In order that the present invention may be more readily understood, certain terms are first defined below. Additional definitions for these and other terms are set forth throughout the specification.
[0040] "Alkyl" As used herein, the term "alkyl" refers to an alkyl group having 1 to 15 carbon atoms. A straight-chain free radical having 1 or a branched saturated hydrocarbon radical ("C 1-15 "alkyl" In some embodiments, the alkyl group has 1 to 3 carbon atoms ("C 1-3 Alkyl "). 1-3 Examples of alkyl groups include methyl (C1), ethyl (C2), n- propyl (C3), and isopropyl (C3). The alkyl group has 8 to 12 carbon atoms (C 8-12 C 8-12 No.A Examples of alkyl groups include n-octyl (C8), n-nonyl (C9), n-decyl (C 10 ) , n-undecyl (C 11 ), n-dodecyl (C 12 ) but is not limited to The prefix "n-" (normal) refers to an unbranched alkyl group. For example, n- C8 alkyl refers to (CH2)7CH3, nC 10 Alkyl is (CH2)9CH 3, etc.
[0041] "Approximately" or "about" As used herein, the term "approximately" or "about" When applied to one or more applicable values, it refers to a value similar to the described reference value. In this document, the terms "approximately" or "about" are used unless otherwise specified or apparent from the context. Unless otherwise specified (where such number exceeds 100% of the possible values), 25%, 20%, 19%, 18% in either direction (greater or smaller) %, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, This refers to a range of values that fall within 7%, 6%, 5%, 4%, 3%, 2%, 1% or less.
[0042] "Amelioration" As used herein, the term "amelioration" refers to the prevention, reduction or means palliative or improvement in the condition of a subject. Improvement means complete recovery or complete resolution of a disease state. In some embodiments, amelioration includes, but is not required to include, prevention of an associated disease. This involves increasing the level of the relevant protein, or its activity, that is lacking in the affected tissue.
[0043] "Amino Acid" As used herein, the term "amino acid" refers in its broadest sense to any It refers to any compound and / or substance that can be incorporated into a polypeptide chain. In some embodiments, the amino acid has the general structure H2N-C(H)(R)-COOH. In some embodiments, the amino acid is a naturally occurring amino acid. In embodiments, the amino acid is a synthetic amino acid, and in some embodiments, In some embodiments, the amino acid is a d-amino acid, and in some embodiments, the amino acid is an l-amino acid. "Standard amino acids" are any of the 20 standard amino acids commonly found in naturally occurring peptides. -amino acids. "Nonstandard amino acids" refer to amino acids that are either synthetic or derived from natural sources. As used herein, the term "amino acid" refers to any amino acid other than the standard amino acids, regardless of whether it is a cyclic or cyclic amino acid. "Synthetic amino acids" include chemically modified amino acids, including salts, amino acid derivatives (amino acids, etc.) The peptides may be carboxy- or carboxyl-substituted, and / or substituted. and / or amino acids, including the amino-terminal amino acid, without adversely affecting their activity. Instead, peptides can be methylated, amidated, or acylated with other chemical groups that can alter the half-life of the peptide. Amino acids may be modified by silylating, protecting groups, and / or substituting. An amino acid may be linked to one or more chemical groups (e.g., a methyl group, Acetate group, acetyl group, phosphate group, formyl moiety, isoprenoid group, sulfate group, polyethylene One of the associations with a glycerol moiety, a lipid moiety, a carbohydrate moiety, a biotin moiety, etc. or post-translational modifications. The term "amino acid" is used interchangeably with "amino acid residue." It is used interchangeably and may refer to free amino acids and / or amino acid residues of peptides. Whether a term refers to a free amino acid or a peptide residue depends on the context in which the term is used. More information will become available.
[0044] "Animal" As used herein, the term "animal" refers to any member of the animal kingdom. In some embodiments, "animal" refers to humans, at any stage of development. In some embodiments, "animal" refers to a non-human animal at any stage of development. In certain embodiments, the non-human animal is a mammal (rodent, mouse, rats, rabbits, monkeys, dogs, cats, sheep, cows, primates, and / or pigs) In some embodiments, the animal is a mammal, a bird, a reptile, an amphibian, a fish, In some embodiments, the worms include, but are not limited to, insects, and / or helminths. Thus, the animals may be transgenic, genetically modified, and / or cloned. .
[0045] "Biologically active" As used herein, the phrase "biologically active" means It refers to the characteristics of any agent that has activity in a biological system, especially in an organism. For example, an agent that, when administered to an organism, has a biological effect on that organism is A protein or polypeptide is considered biologically active. In certain embodiments, at least one biological sequence of the protein or polypeptide of interest is The portions of a protein or polypeptide that share a common biological activity are generally referred to as "biologically active " part.
[0046] "Delivery" The term "delivery" when used in connection with CNS delivery includes delivery of mRNA. is delivered intracellularly into neurons, and the encoded protein is expressed in the neurons. The mRNA is delivered intracellularly in neurons and the encoded protein is expressed. , CSF, and the like, and provided by other neurons.
[0047] "Expression" As used herein, "expression" of a nucleic acid sequence refers to one or more of the following events: (1) generation of an RNA template from a DNA sequence (e.g., by transcription); (2) RNA transcription Processing of products (splicing, editing, 5' capping and / or 3' cleavage) (3) translation of the RNA into a polypeptide or protein; and / or (4) Post-translational modification of a polypeptide or protein. As used herein, the terms "expression" and "production" refer to The terms and grammatical equivalents are used interchangeably.
[0048] "Fragment" As used herein, the term "fragment" refers to a polypeptide, Any isolated feature in a particular polypeptide that is unique or characteristic of that polypeptide. As used herein, the term refers to at least a portion of a full-length polypeptide. It also refers to any isolated portion of a particular polypeptide, which retains some activity. Alternatively, the active portion that is retained is at least 10% of the activity of the full-length polypeptide. More preferably, the active portion that is retained has at least 20%, 30% or more of the activity of the full-length polypeptide. 0%, 40%, 50%, 60%, 70%, 80% or 90%. Preferably, the retained active portion has at least 95%, 96%, 97%, or 100% of the activity of the full-length polypeptide. 7%, 98% or 99%. Most preferably, the active portion retained is the full-length polypeptide. As used herein, the term refers to a peptide having at least the full length Any portion of a particular polypeptide that contains defined sequence elements found in the polypeptide. Preferably, the sequence elements are at least 4 to 5, more preferably the full-length polypeptide. At least about 10, 15, 20, 25, 30, 35, 40, 45, 50 or more ami of the chid This extends to acids.
[0049] "Functional" As used herein, a "functional" biomolecule is one that has been characterized. A biomolecule is a biological molecule in a form that exhibits certain properties and / or activities.
[0050] "Half-life" As used herein, the term "half-life" refers to the life of a nucleic acid or protein. The time it takes for a quantity, such as a concentration or activity, to fall to half its initial measured value over a period of time. It is the time to do so.
[0051] "Improve," "Increase," or "Decrease" As used herein, "improve" means The terms "to increase," "to increase," or "to decrease," or grammatical equivalents, are used to A fixed value, e.g., a value measured in the same individual before the initiation of the treatment described herein, or Measurements in a control sample (or samples) in the absence of the treatments described herein. The values are compared to a reference value. "Control samples" are samples that have the same form of the disease as the samples being treated. The subjects were suffering from and were approximately the same age as the subjects receiving treatment.
[0052] "In Vitro" As used herein, the term "in vitro" means Refers to phenomena that occur in artificial environments, e.g. in test tubes, rather than in multicellular organisms. , or in a reactor, cell culture medium, etc.
[0053] "In Vivo" As used herein, the term "in vivo" refers to a human It refers to phenomena that occur in multicellular organisms, including humans and animals. In this context, the term refers to living cells (as opposed to, e.g., in vitro systems). It may also be used to refer to a phenomenon occurring within
[0054] "Intrathecal Administration" As used herein, the term "intrathecal administration" or "intrathecal injection" refers to The term refers to injection into the spinal canal (the intrathecal space surrounding the spinal cord). Burr hole, cisterna magna, or lumbar puncture A variety of techniques may be used, including, but not limited to, lateral ventricular injection through a needle or the like. In some embodiments, "intrathecal administration" or "intrathecal delivery" according to the present invention is not provided. " refers to IT administration or delivery via the lumbar spinal region or area, i.e., lumbar IT administration or As used herein, the term "lumbar region" or "lumbar area" refers to delivery to the third and the fourth lumbar vertebra (lower back), more generally referring to the L2-S1 region of the spine .
[0055] "Lower Motor Neuron" As used herein, the term "lower motor neuron" refers to the motor neurons that connect the brainstem and spinal cord to muscle fibers. In other words, the lower motor neurons Neurons carry nerve impulses from upper motor neurons to muscles. The axons of the lower motor neurons terminate in the effectors (muscles). ron" and "spinal cord anterior horn cells."
[0056] "Lysosomal Enzyme" As used herein, the term "lysosomal enzyme" refers to a mammalian or to reduce the accumulation of one or more lysosomal storage substances in the lysosomes of the The term "lysozyme" refers to any enzyme that can rescue or ameliorate the symptoms of a lysozyme. Lysosomal enzymes include both wild-type and modified lysosomal enzymes, and may be produced by recombinant methods and They can be produced using synthetic methods or purified from natural sources. Examples of enzymes are listed in Table 2.
[0057] "Lysosomal enzyme deficiency" As used herein, "lysosomal enzyme deficiency" refers to a lysosomal enzyme deficiency. In the endothelium, macromolecules (e.g., enzyme substrates) are transported into peptides, amino acids, monosaccharides, nucleic acids, and fatty acids. A genetic disorder caused by a deficiency in at least one of the enzymes required to break down As a result, individuals suffering from lysosomal enzyme deficiencies have Accumulates substances in the body (e.g., CNS, liver, spleen, intestines, blood vessel walls, and other organs) .
[0058] "Lysosomal storage disease" As used herein, the term "lysosomal storage disease" means Caused by a deficiency of one or more lysosomal enzymes required to metabolize natural macromolecules This refers to any disease that results in the accumulation of undegraded molecules in the lysosomes. These diseases and various examples are: This is described in detail below.
[0059] "Messenger RNA (mRNA)" As used herein, "messenger RNA (mRNA)" refers to a "NA (mRNA)" is a polynucleotide that encodes at least one polypeptide. As used herein, mRNA refers to both modified and unmodified RNA. mRNA includes one or more coding regions and non-coding regions. mRNA may be purified from natural sources or produced using recombinant expression systems. The nucleic acid may be optionally purified or chemically synthesized. In the case of molecules synthesized in vitro, the mRNA is chemically modified, with modifications to the bases, sugars, backbone, etc. The mRNA sequence may include nucleoside analogs such as analogs having the following structure: In some embodiments, the mRNA is in a 5' to 3' orientation, unless otherwise specified. Natural nucleosides (e.g., adenosine, guanosine, cytidine, uridine), nucleosides Cytosine analogues (2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine , 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-cytidine, Ropinyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine Lysine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine adenosine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaadenosine, Zaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine and 2-thiocytidine), chemically modified bases, biologically modified bases (e.g., methyl modified bases), intervening bases, modified sugars (e.g., 2'-fluororibose, ribose, 2 '-deoxyribose, arabinose and hexose), and / or modified phosphate groups (e.g. For example, phosphorothioate and 5'-N-phosphoramidite linkages.
[0060] "Nucleic Acid" As used herein, the term "nucleic acid" refers in its broadest sense to any polynucleotide. It refers to any compound and / or substance that can be incorporated into an oxidase chain. In some embodiments, nucleic acids can be incorporated into a polynucleotide chain via a phosphodiester bond. In some embodiments, a "nucleic acid" is a compound and / or substance that Refers to a nucleic acid residue (e.g., a nucleotide and / or a nucleoside). In the present context, "nucleic acid" refers to a polynucleotide chain that includes individual nucleic acid residues. In some embodiments, "nucleic acid" refers to RNA, as well as single-stranded and / or double-stranded DNA. , and / or cDNA.
[0061] "Patient" As used herein, the term "patient" or "subject" refers to a subject, e.g., an experimental The compositions provided herein are intended for the purposes of diagnosis, prophylactic, cosmetic, and / or therapeutic administration of the above-mentioned compounds. A typical patient is an animal (e.g., a mouse, rat, rabbit, etc.) In some embodiments, the mammals include, but are not limited to, reptiles, non-human primates, and / or humans. In the present invention, the patient is a human, which includes pre- and post-natal forms.
[0062] "Pharmaceutically acceptable" As used herein, the term "pharmacologically acceptable" means has the discretion, within the scope of sound medical judgment, to determine whether there is undue toxicity, irritation, allergic reaction, or other problem, or uncomplicated, suitable for use in contact with human and animal biological tissues, with reasonable benefit / risk This refers to a substance that corresponds to the ratio of
[0063] "Pharmaceutically acceptable salts" Pharmaceutically acceptable salts are known in the art. For example, SM Berge et al. have described pharma- ceutically acceptable salts in detail in J. Pharmac. The present invention is described in European Journal of Neurosciences (1977) 66:1-19. Pharmaceutically acceptable salts of the compounds in the above are prepared by the addition of suitable inorganic and organic acids and organic bases. Examples of pharma- ceutically acceptable, non-toxic acid addition salts include those derived from hydrochloric acid, hydrobromic acid, Inorganic acids such as acetic acid, oxalic acid, maleic acid, Organic acids such as tartaric acid, citric acid, succinic acid or malonic acid, or ion exchange Salts of amino groups formed using other methods used in the prior art. Pharmaceutically acceptable salts include adipates, alginates, ascorbates, asparagides, and the like. Phosphates, benzenesulfonates, benzoates, hydrogen sulfates, borates, acetates, camphor Salt, camphorsulfonate, citrate, cyclopentanepropionate, diglycerate Conate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptone Salts, glycerophosphates, gluconates, hemisulfates, heptanoates, hexanoates, iodides, Hydrogen nitrate, 2-hydroxyethanesulfonate, lactobionate, lactate, lauryl Phosphate, lauryl sulfate, malate, maleate, malonate, methanesulfonate , 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, paclitaxel Lumitate, pamoate, pectinate, peroxosulfate, 3-phenylpropionate Salt, phosphate, picrate, pivalate, propionate, stearate, succinate Salts, sulfates, tartrates, thiocyanates, p-toluenesulfonates, undecanoates Salts derived from appropriate bases include alkali metal, alkaline earth metal, valerate, and the like. Ammonium and N + (C 1-4 Representative alkali or alkalyl salts. Potassium earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Further pharma- ceutically acceptable salts include, where appropriate, non-toxic ammonium salts, quaternary ammonium salts, and the like. monium and, for example, halides, hydroxides, carboxylates, sulfates, phosphates, Formed with counterions such as nitrates, sulfonates, and arylsulfonates Further pharma- ceutically acceptable salts include, for example, quaternary alkylamino The quaternization of amines using suitable electrophiles such as alkyl halides to form salts containing the group This includes salts formed by condensation.
[0064] "Subject" As used herein, the term "subject" refers to any subject, human or non-human. Any animal (e.g., mouse, rat, rabbit, dog, cat, cow, pig, sheep, horse, etc.) Human refers to human beings (primates, mammals, or primates). Human includes prenatal and postnatal forms. In many embodiments, In the present invention, the subject is a human. A "subject" may be a patient, and may be a subject for diagnosis or treatment of a disease. As used herein, the term "specimen" refers to a human being presented to a health care provider for " or "patient." A subject is someone who is afflicted with a disease or disorder or A person may be affected, but may or may not show symptoms of the disease or disorder.
[0065] "Therapeutically Effective Amount" As used herein, the term "therapeutically effective amount" of a therapeutic agent , to treat, diagnose, prevent, and / or delay the onset of symptoms of a disease, disorder, and / or abnormality. to a subject suffering from or susceptible to a disease, disorder, and / or condition in order to A therapeutically effective amount generally refers to a dosage that contains at least one unit dose. The amount to be administered according to the regimen will be understood by one of skill in the art.
[0066] "Treatment" As used herein, "treatment" (also "treat" or "treating") The term inflammatory bowel disease (IGD) refers to a specific disease, disorder, and / or condition (e.g., influenza). partially or completely alleviates the prevalence of one or more symptoms, characteristics, and / or causes of ameliorate, revive, suppress, delay the onset, reduce the severity, and / or reduce The treatment refers to any administration of a substance (e.g., a provided composition) that is effective to treat a related disease, Specimens that show no signs of disease, disorder, and / or abnormality, and / or Alternatively or additionally, the test may concern specimens that show only early signs of abnormality. Treatment is performed on specimens that exhibit one or more confirmed symptoms of the relevant disease, disorder, and / or abnormality. In some embodiments, treatment may involve treating an associated disease, disorder, and / or It may also concern a subject who has been diagnosed with a disorder. Treatment is associated with an increased risk of developing a related disease, disorder, and / or condition. It is also useful for samples that are believed to have one or more statistically correlated susceptibility factors. stomach.
[0067] "Upper motor neuron" As used herein, "upper motor neuron" and "cortical The term "spinal neurons" refers to neurons that arise in the motor cortex of the cerebral cortex or in the brainstem and form the final common pathway. It is used as a synonym for the motor neurons that transmit motor information from the upper A distal motor neuron is any motor neuron that is not directly responsible for innervating a target muscle. This refers to the Detailed Description
[0068] The present invention relates in particular to a method for efficiently delivering messenger RNA (mRNA) to the central nervous system (CNS). In particular, the present invention provides methods and compositions for delivering a therapeutically effective amount of ... or in neurons in the spinal cord. The present invention relates to a method for delivering a composition comprising an mRNA encoding a protein encapsulated in a medicament. The present invention provides methods and compositions for intrathecal administration to elephants of CNS disorders such as spinal muscular atrophy. As used herein, "liposomes" are particularly useful in treating systemic diseases, disorders, or conditions. The term "lipid nanoparticle vesicle" refers to any lamellar, multi-lamellar, or solid lipid nanoparticle vesicle. Generally, liposomes as used herein are formed by mixing one or more lipids. or by mixing one or more lipids with a polymer. As used herein, the term "liposome" refers to both lipid and polymer-based nanoparticles. In some embodiments, liposomes suitable for the present invention include cationic or non-ionic liposomes. These include cationic lipids, cholesterol-based lipids, and PEG-modified lipids.
[0069] Various aspects of the invention are described in detail in the following sections. Each section may be applicable to any aspect of the present invention. "Or" means "and / or" unless otherwise stated. mRNA associated with CNS diseases, disorders, or disorders
[0070] The present invention can be used to deliver any mRNA to the central nervous system. The present invention relates to a method for identifying a protein that is associated with or implicated in a CNS disease, disorder, or abnormality. As used herein, the term "CNS disease, disorder" refers to a neurodegenerative disease, including a central nervous system (CNS) disorder, or a neurodegenerative disease. "Damage or abnormality" refers to one or more neuronal functions of the central nervous system (i.e., the brain and / or spinal cord). In some embodiments, a CNS disorder refers to a disease, disorder, or abnormality that affects the functioning of the CNS. The disease, disorder, or abnormality occurs in neurons of the CNS (i.e., the brain and / or spinal cord). It may be caused by a protein deficiency or dysfunction.
[0071] Typical CNS diseases, disorders, or abnormalities include acid lipase deficiency, acid maltase deficiency, , Acquired epileptic aphasia, Acute disseminated encephalomyelitis, Hyperactivity syndrome, Adie's pupil, Adie's syndrome syndrome, adrenoleukodystrophy, agnosia, Aicardi syndrome, Aicardi-Goutière syndrome Syndromic disorders, Alexander disease, Alpers disease, alternating hemiplegia, Alzheimer's disease, muscle atrophy Aneurysm of the brain, ALS, anencephaly, Angelman syndrome, hemangiomatosis, anoxia , antiphospholipid syndrome, aphasia, apraxia, arachnoiditis, Arnold-Chiari malformation, Asperger's syndrome Ruger syndrome, ataxia, ataxia-telangiectasia, ataxia and cerebellar or spinocerebellar Degeneration, Attention Deficit Hyperactivity Disorder, Autism, Autonomic Dysfunction, Barth Syndrome, Batten Disease , Becker myotonia, Behçet's disease, Bell's palsy, Bernard-Ross syndrome, Bingsworth syndrome Infantilism, Incontinentia pigmenti, Bradbury-Eggleston syndrome, Spinal hemiplegia, Spinal-bulbar myopathy atrophy, kadasil, canavan disease, burning pain, cavernoma, cavernous hemangioma, central cervical spinal syndrome, spine Central myelin syndrome, central pontine myelinolysis, ceramidase deficiency, cerebellar degeneration, cerebellar hypoplasia, cerebral peduncle Cerebral gigantism, cerebral palsy, cerebro-oculofacial syndrome (COFS), cholesterol ester accumulation Chorea, chorea, chorea-acanthocytosis, chronic inflammatory demyelinating polyneuropathy (CIDP) , chronic orthostatic intolerance, Cockayne syndrome type II, Coffin-Lowry syndrome, colposcopy Farley, congenital myasthenia, corticobasal degeneration, cranial arteritis, Kreutz encephalitis Feldt-Jakob syndrome, Cushing's syndrome, cytomegalic inclusion disease, dancing eyes disease Dandy-Walker syndrome, Dawson's disease, septo-optic dysplasia, Gerin-Klumpke palsy, dentatoruclear cerebellar atrophy, dentatorubral atrophy, dermatomyositis, developmental integrative movement Movement disorder, neuromyelitis optica, diffuse sclerosis, severe myoclonic epilepsy in infancy, autonomic neuropathy , dysgraphia, dyslexia, swallowing disorder, conduct disorder, myoclonic cerebellar synkinesis disorder, cerebellar dyssynchrony, Fabry disease, Fahr's disease, familial dysautonomia, familial hematopoietic syndrome Tuberculosis, idiopathic familial basal ganglia calcification, familial periodic paralysis, familial spastic paralysis, Barr's disease, fibromuscular dysplasia, Fisher's syndrome, hypotonia syndrome, Friedreich's movement syndrome Ataxia, Gaucher disease, systemic gangliosidosis, Gerstmann syndrome, Gerstmann-Sch Strößler-Scheinker syndrome, giant axonal neuropathy, giant cell arteritis, giant cell Alveolar inclusion disease, globoid cell leukodystrophy, glossopharyngeal neuralgia, glycogen storage disease, Guillain-Barré syndrome syndrome, Hallervorden-Spatz disease, persistent hemicrania, crossed hemiplegia, hereditary spastic paraparesis Hereditary ataxia of the polyneuropathy type, Holmes-Adie syndrome, holoprosencephaly, Hughes syndrome syndrome, Huntington's disease, hydranencephaly, hydromyelia, hypercortisolism, immune-mediated, encephalomyelitis, Inclusion body myositis, incontinentia pigmenti, childhood hypotonia, infantile neuroaxonal dystrophy, acidosis, Foramen cephalus, Isaacs syndrome, Joubert syndrome, Kearns-Sayre syndrome, Kennedy syndrome Kinsbourne syndrome, Klein-Levin syndrome, Klippel-Fehr syndrome syndrome, Klippel-Trenanoni syndrome (KTS), Klüver-Bucy syndrome, Korsakoff amnesia syndrome, Krabbe disease, Kugel-Welander disease, Lambert-Eaton Myasthenic syndrome, Landau-Kleffner syndrome, Lateral femoral cutaneous nerve entrapment, Bulbar Lateral lateral syndrome, Leigh's disease, Lennox-Gastaut syndrome, Lesch-Nyhan syndrome, Leva In-Critchley syndrome, Lewy body dementia, lipoid proteinosis, lissencephaly, Immunodeficiency syndrome, Lou Gehrig's disease, neurological sequelae of lupus, Lyme disease, Machado Joseph disease, macrocephaly, Melkerson-Rosenthal syndrome, Menkes disease, dysesthesias femoris, Metachromatic leukodystrophy, microcephaly, Miller-Fisher syndrome, Moebius syndrome, multifocal Myasthenia gravis, myelinoclastic diffuse sclerosis, Narcolepsy, neuroacanthocytosis, neurofibromatosis, neuroleptic malignant syndrome, neuropathies Sarcoidosis, Niemann-Pick disease, Otahara syndrome, olivopontocerebellar atrophy, opsonopathy Clonus-myoclonus, O'Sullivan-McLeod syndrome, pantothenate kinase-related Neurodegeneration, paraneoplastic syndromes, paresthesia, Parkinson's disease, paroxysmal choreoathetosis, Hemicrania, Parry-Romberg, Pelizaeus-Merzbacher disease, Pena Shocker II syndrome, periventricular leukomalacia, phytanic acid storage disease, Pick's disease, piriformis syndrome, multifocal Myositis, Pompe disease, Post-polio syndrome, Primary dentate atrophy, Primary lateral sclerosis, Primary progressive aphasia, prion disease, progressive facial hemiatrophy, progressive gait ataxia, progressive multifocal white matter Encephalopathy, Progressive sclerosing poliodystrophy, Progressive supranuclear palsy, Prosopagnosia, Ramsay-Hall Rett syndrome I, Ramsay Hunt syndrome II, Rasmussen's encephalitis, Refsum disease, Rett syndrome syndrome, Reye's syndrome, Riley-Day syndrome, Sandhoff disease, Schilder's disease, Seitelberg syndrome Shy-Drager syndrome, Severe Myoclonic Epilepsy in Infancy (SMEI), Shy-Drager syndrome, Glenn syndrome, spasticity, spina bifida, spinal muscular atrophy, spinocerebellar atrophy, spinocerebellar degeneration, spinal cord injury Teal-Richardson-Olszewski syndrome, Striatonigral degeneration, Sturge-Weinstein syndrome Barr syndrome, tardive dyskinesia, Tay-Sachs disease, thoracic outlet syndrome, thyrotoxicosis Opathy, painful tics, Todd's palsy, trigeminal neuralgia, tropical spastic paraparesis, Troya syndrome, von Echonomo disease, von Hippel-Lindau disease (VHL), von Lehmann disease Klinghausen's disease, Wallenberg syndrome, Werdnig-Hoffmann disease, Wernicke syndrome Keighley-Korsakoff syndrome, West syndrome, Whipple disease, Williams syndrome, Wilso These include, but are not limited to, Schneider's disease, Wolman disease, X-linked spinal-bulbar muscular atrophy, and Zellweger syndrome. Not limited. Motor neuron disease
[0072] In some embodiments, the CNS disease, disorder, or abnormality is one of the motor neurons. Any disease, disorder, or abnormality that affects the above functions, also known as motor neuron disease. In some embodiments, the motor neuron disease is a neurodegenerative disease that affects the CNS (i.e., the brain and / or is caused by a protein deficiency or dysfunction in motor neurons of the spinal cord. As used herein, the term "motoneuron" refers to a neuron that controls the activity of voluntary muscles. In general, motor neurons are classified into upper motor neurons and lower motor neurons. As used herein, "upper motor neurons" refers to neurons in the cerebral cortex. Motor neurons originate in the motor cortex or brainstem and carry motor information to the final common pathway. Upper motor neurons are also called "corticospinal neurons." A distal motor neuron is any motor neuron that is not directly responsible for stimulating a target muscle. As used herein, the term "lower motor neuron" refers to the neurons in the brainstem and spinal cord. The term refers to the motor neurons that connect the spinal cord to muscle fibers. In other words, lower motor neurons They carry nerve impulses from motor neurons to muscles. Generally, the axons of lower motor neurons: The lower motor neurons are classified as "spinal neurons" and "spinal Includes "medullary anterior horn cells."
[0073] Typical motor neuron diseases, disorders, or abnormalities include amyotrophic lateral sclerosis (ALS), primary Progressive lateral sclerosis (PLS), pseudobulbar palsy, hereditary spastic paraplegia, progressive muscular atrophy (PMA) , progressive bulbar palsy (PBP), distal hereditary motor neuropathy, and spinal muscular atrophy. However, there is no particular limitation.
[0074] In some embodiments, the motor neuron disease, disorder, or abnormality is spinal muscular atrophy. A group of spinal muscular atrophies are characterized by degeneration of lower motor neurons. It is a genetically and clinically heterogeneous group of rare debilitating disorders that affect the anterior horn of the spinal cord. The degeneration of cells within the lower motor neurons, also known as muscular atrophy, can lead to the atrophy of various muscle groups in the body. This group of diseases includes the root, They can be divided into distal, autosomal recessive proximal and focal spinal muscular atrophies. Considering that protein deficiency is a major cause in various forms of spinal muscular atrophy, The disease components are usually classified according to the gene(s) involved in the disorder. Six major groups of diseases are described. [Table 1-1] [Table 1-2] Disorders involving CNS components
[0075] In some embodiments, the CNS disease, disorder, or abnormality is related to a CNS component. In general, diseases related to CNS components affect both the CNS and peripheral tissues in the body. and one or more biological tissues, one or more CNS etiologies and / or diseases, For example, in some embodiments, Protein deficiency can occur due to the loss of intracellular and / or extracellular components, e.g., glycosaminoglycans ( Excessive accumulation of proteins, such as GAGs, lipids, plaques (i.e., β-amyloid), or proteins. Thus, in some embodiments, the CNS components The disease is a lysosomal storage disorder caused by a deficiency of lysosomal enzymes, which results in the Excessive accumulation of glycosaminoglycans (GAGs) in both NS and peripheral tissues It is.
[0076] In some embodiments, lysosomal storage diseases having CNS etiology and / or symptoms Aspartylglucosaminuria, cholesterol ester storage disease, Wolman disease, and Schizosaccharomyces cerevisiae Swinouflage, Danon disease, Fabry disease, Farber lipogranulomatosis, Farber disease, Fucositis storage disease, galactosialidosis type I / II, Gaucher disease type I / II / III, Roboid cell leukodystrophy, Krabbe disease, Glycogen storage disease II, Pompe disease, GM1 ganglion Gangliosidosis type I / II / III, GM2 gangliosidosis type I, T-gangliosidosis type II Sachs disease, GM2 gangliosidosis type II, Sandhoff disease, GM2 ganglioside mannosis, α-mannosidosis type I / II, β-mannosidosis, metachromatic leukodystrophy Roffey, mucolipidosis type I, sialidosis types I / II, mucolipidosis II Type III / III, I-cell disease, mucolipidosis IIIC, pseudo-Hurler multiple dystrophy , mucopolysaccharidosis type I, mucopolysaccharidosis type II, mucopolysaccharidosis type IIIA, Sanfilippo syndrome, Mucopolysaccharidosis type IIIB, Mucopolysaccharidosis type IIIC, Mucopolysaccharidosis IIID, Mucopolysaccharidosis Type IVA, Morquio syndrome, mucopolysaccharidosis type IVB, mucopolysaccharidosis type VI, mucopolysaccharidosis V Type II, Sly syndrome, mucopolysaccharidosis type IX, multiple sulfatase deficiency, neurosarcoma Lloyd-lipofuscinosis, CLN1 Batten disease, CLN2 Batten disease, Niemann-Pick disease Type A / B, Niemann-Pick disease type C1, Niemann-Pick disease type C2, pyknodysostosis, syn including, but not limited to, Dollar disease types I / II, Gaucher disease, and sialic acid storage diseases. stomach.
[0077] A detailed review of the genetic etiology, clinical manifestations, and molecular biology of lysosomal storage disorders is available in Scrivener's Journal of Clinical Oncology. er et al., eds., The Metabolic and Molecule ar Basis of Inherited Disease,7.sup.th E d., Vol. II, McGraw Hill, (1995). The enzyme deficiencies in the above diseases are known to those skilled in the art, some of which are illustrated in Table 2 below. do. [Table 2-1] [Table 2-2] [Table 2-3]
[0078] In various embodiments, the present invention relates to a method for treating any of the CNS disorders described herein, To deliver mRNA that codes for a protein that is missing in a disorder or abnormality In some embodiments, the present invention may be used to treat motor neuron diseases, For example, the m gene encoding the protein that is defective in the motor neuron diseases shown in Table 1 In certain embodiments, the present invention may be used to deliver RNA to spinal cord. Muscle atrophy (SMA), e.g., defects in SMN1, which are described in detail below. In some embodiments, the method may be used to deliver mRNA encoding a protein that is In one embodiment, the present invention provides a method for the treatment of lysosomal storage disorders in which a CNS component is deficient. In some embodiments, the endothelial cell may be used to deliver mRNA encoding a endothelial enzyme. In one embodiment, the present invention provides a method for delivering an mRNA encoding a lysosomal enzyme selected from Table 2. In some embodiments, the m The RNA may encode a wild-type or naturally occurring amino acid sequence. In an embodiment, the mRNA suitable for use in the present invention is a wild-type or naturally occurring In some embodiments, the mRNA suitable for the present invention may be an amino acid sequence. A may be a codon-optimized sequence. In the present invention, preferred mRNAs are those encoding amino acid sequences having substantial homology thereto, or those encoding sequences having similar sequences to those of the wild type. A native or naturally occurring amino acid protein sequence (e.g., a wild-type or naturally occurring and at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 95%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500%, 510%, 520%, In one embodiment, sequences having identical sequences (0%, 85%, 90%, 95%, 98%, identical sequences) can be identified. Survival Motor Neurons
[0079] In some embodiments, the methods and compositions provided herein include, but are not limited to, spinal cord injury. Encoding survival motor neuron proteins into the CNS for the treatment of SMA Used to deliver mRNA.
[0080] A suitable SMN mRNA substitutes for the activity of the naturally occurring SMN protein. or rescue one or more phenotypes or symptoms associated with spinal muscular atrophy. The gene may encode any full length, fragment, or portion of the SMN protein. The mRNA sequence of human motor neuron-1 (hSMN-1) and representative wild-type or natural The corresponding amino acid sequences of the hSMN-1 protein present in are shown in Table 3. [Table 3-1] [Table 3-2]
[0081] Thus, in some embodiments, the mRNA suitable for the present invention is wild-type hSM N-1 mRNA sequence (SEQ ID NO: 1). In some embodiments, a suitable mRNA NA is a codon-optimized hSMN-1 mRNA sequence represented by (SEQ ID NO:3). It's fine. AUGGCCAUGAGCAGCGGAGGCAGCGGCGGAGGAGUGCCC GAGCAGGAGGACAGCGUGCUGUUCAGGAGAGGCACCGGCC AGAGCGAUGACAGCGAUAUCUGGGACGAUACCGCUCUGAU CAAGGCCUACGACAAGGCCGUGGCCAGCUUCAAGCACGCC CUGAAAAACGGCGACAUCUGCGAGACCAGCGGCAAGCCCA AGACAACCCCCAAGAGAAAGCCCGCCAAGAAGAAUAAGAG CCAGAAAAAAAGAACACCGCCGCCAGCCUGCAGCAGUGGAAG GUGGGCGACAAGUGCAGCGCCAUCUGGAGCGAGGACGGCU GCAUCUACCCCGCCACCAUCGCCAGCAUCGACUUCAAGAG AGAGACCUGCGUGUGUCGUGUACACCGGCUACGGCAACAGA GAGGAGCAGAACCUGAGCGACCUGCUGAGCCCCAUUUGUG AGGUGGCCAAUAACAUCGAACAGAACGCCCAGGAGAACGA GAAUGAAAGCCAGGUGAGCACCGACGAGAGGCGAGAACAGC AGAUCUCCUGGCAACAAGAGCGACAACAUCAAGCCUAAGU CUGCCCCUUGGAACAGCUUCCUGCCCCCUCCUCCACCCAU GCCCGGACCCAGACUGGGACCCGGAAAACCUGGCCUGAAG UUCAACGGACCACCUCCCCCCUCCACCUCCUCCCCACCUC AUCUCCUGAGCUGCUGGCUGCCACCCUUCCCCAGCGGACC CCCUAUCAUCCCACCACCCCCUCCCAUCUGCCCCGACAGC CUGGACGACGCCGAUGCCCUGGGCAGCAUGCUGAUCAGCU GGUACAUGAGCGGCUACCACACAGGAUACUACAUGGGCUU CAGACAGAACCAGAAGGAGGGCAGAUGCUCCCACUCCCUG AACUGA
[0082] Alternatively, in some embodiments, a suitable mRNA is represented by (SEQ ID NO:4): , a codon-optimized hSMN-1 mRNA sequence. AUGGCCAUGAGCAGCGGAGGAAGCGGAGGAGGAGUGCCA GAACAGGAAGAUAGCGUGCUGUUUCGCCGGGGCACCGGAC AAUCGGACGACAGCGAUAUUUGGGACGACACUGCGCUCAU CAAGGCCUACGACAAGGCGGUGGCUUCGUUCAAGCACGCU CUGAAGAACGGGGAUAUCUGUGAAACCAGCGGUAAACCAA AAACUACGCCGAAAAGGAAACCCGCCAAAAAGAACAAGUC ACAGAAGAAGAAUACCGCUGCGAGCUUGCAGCAGUGGAAG GUGGGCGACAAGUGCUCCGCGAUUUGGUCGGAAGAUGGUU GCAUCUACCCGGCAACCAUCGCCUCCAUCGACUUUAAGCG GGAGACUUGCGUGUGGUCUACACCGGAUACGGCAAUAGA GAGGAACAGAAUCUGUCAGACCUUCUGUCGCCAAUCUGCG AGGUCGCCAACAAUAUCGAACAAAACGCCCAAGAGAACGA GAAUGAGUCCCAAGUGUCCACGGACGAAUCGGAAAACUCA CGGUCCCCUGGGAACAAGUCAGAUAACAUCAAGCCUAAAU CGGCACCAUGGAACUCCUUCCUGCCGCCUCCGCCUCCGAU GCCGGGCCCGCGCCUGGGACCGGGUAAACCCGGGCUCAAG UUCAAUGGACCGCCACCCCCACCCCCGCCACCGCCGCCCC ACCUCCUCUCGUGCUGGCUGCCGCCGUUCCCUUCCGGACC GCCUAUCAUUCCGCCACCUCCACCUAUCUGCCCAGACAGC CUGGAUGAUGCCGACGCAUUGGGCUCCAUGCUCAUCUCAU GGUACAUGUCGGGAUACCAUACUGGGGUAUUACAUGGGCUU CAGACAGAACCAGAAGGAAGGACGCUGUUCCCAUAGCCUG AACUAG
[0083] In some embodiments, the preferred mRNA is human survival motor neuron-2 (hSM N-2) protein. corresponding to the amino acid sequence of a typical wild-type or naturally occurring hSMN-2 protein, The RNA sequences are shown in Table 4. [Table 4-1] [Table 4-2]
[0084] Thus, in some embodiments, the mRNA suitable for the present invention is wild-type hSM N-2 mRNA sequence (SEQ ID NO:5). In some embodiments, a suitable mRNA The NA can be a codon-optimized hSMN-1 mRNA sequence.
[0085] In some embodiments, a suitable mRNA sequence is human SMN-1 (SEQ ID NO:2) or or an mRNA sequence encoding a homolog or analog of human SMN-2 (SEQ ID NO:6). For example, human SMN-1 or SMN-2, protein homologs or analogs. retains essential SMN-1 or SMN-2 protein activity and is The human SMN-1 protein (e.g., SEQ ID NO: 2) or the human SMN-2 protein When compared to the protein (e.g., SEQ ID NO: 6), one or more amino acid substitutions, deletions, and and / or an insertion, In some embodiments, the mRNA suitable for the present invention is SEQ ID NO:2. or SEQ ID NO: 6 and at least 50%, 55%, 60%, 65%, 70%, 75%, 8 0%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 9 8%, 99% or more homologous to the amino acid sequence. In one embodiment, the mRNA suitable for use in the present invention is a mRNA encoding the human SMN-1 protein (SEQ ID NO:2 ) or a protein substantially identical to the human SMN-2 protein (SEQ ID NO: 6). In some embodiments, the mRNA suitable for the present invention is SEQ ID NO:2. or a mixture of SEQ ID NO:6 and at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, %, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% In some embodiments, the amino acid sequence is encoded by a sequence that is 99% identical or more identical to the sequence of the original amino acid. In the present invention, the preferred mRNA is a human SMN-1 protein or a human SMN -2 protein fragment or portion thereof, SMN-1 or SMN-2 have activities similar to those of their respective wild-type proteins. In some embodiments, the present invention is suitable for The mRNA is at least one of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5. 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher It comprises one nucleotide sequence.
[0086] The human SMN-1 gene undergoes alternative processing and transcriptional modification, resulting in alternative splice amplicons. For example, there are five known hSMN-1 splice isoforms. There are three isoforms of human SMN-1: b, c, e, f, and g. The 2 genes also undergo alternative processing and transcriptional modification to produce alternative splice isoforms. There are four known hSMN-2 splice isoforms: hSMN In some embodiments, the present invention provides the -2 isoforms a, b, c, and d. Specifically, hSMN-1 isoforms (e.g., isoforms b, c, e, f, or g) In some embodiments, the present invention is used to deliver an mRNA encoding encodes an hSMN-2 isoform (e.g., isoform a, b, c, or d) It is used to deliver mRNA that targets hSMN-1 and hSMN-2 isoforms. The nucleotide and amino acid sequences of the polypeptides are known in the art. In an embodiment, the present invention relates to a method for the detection of hSMN-1 isoform or hSMN-2 protein. can be used to deliver mRNA encoding proteins or their isoforms. In some embodiments, the mRNA suitable for use in the present invention is a wild-type or naturally occurring The sequence may be the hSMN-1 or hSMN-2 isoform sequence present in In some embodiments, the mRNA suitable for the present invention is a codon-optimized, hS In some embodiments, the sequence may be a hSMN-1 or hSMN-2 isoform sequence. In the present invention, the preferred mRNA contains an amino acid sequence having substantial homology thereto. or wild-type or naturally occurring hSMN-1 or hSMN-2 isoforms. hSMN-1 or hSMN-2 soform sequence and at least 50%, 55%, 60%, 65%, 70%, 75%, 80% %, 85%, 90%, 95%, 98% sequence homology) can be identified. Synthesis of mRNA
[0087] The mRNA according to the present invention can be synthesized by any of a variety of known methods. For example, The mRNA according to the present invention can be synthesized by in vitro transcription (IVT). Briefly, IVT is a process that generally involves the release of a promoter, a pool of ribonucleotide triphosphates, , a buffer system which may contain DTT and magnesium ions, and a suitable RNA polymerase (e.g., T3, T7, or SP6 RNA polymerase), deoxyribonuclease Contains nuclease I, pyrophosphatase, and / or ribonuclease inhibitors The procedure can be performed using either linear or circular DNA templates. The exact conditions depend on the specific application. will vary depending on the
[0088] In some embodiments, for the preparation of mRNA according to the present invention, a DNA template is The template is transcribed in vitro. A suitable DNA template is generally In vitro transcription followed by the desired nucleotide sequence appropriate for the RNA and termination signal. For example, a promoter such as the T3, T7, or SP6 promoter do.
[0089] The desired mRNA sequence according to the present invention can be synthesized by PCR using standard techniques into a DNA template. For example, starting with a desired amino acid sequence (e.g., an enzyme sequence), The reverse transcription of the DNA is carried out based on the altered genetic information. Generally, the G / C content can be used to select the best G / C codons. On the other hand, the tRNP sequence can be optimized to achieve a high C content depending on the codon usage. The optimized RNA sequence is designed to maximize the frequency of A. With the aid of the positioning and comparison with the original (wild type) sequence, the expression Secondary structures can also be used to determine the stabilizing and destabilizing properties of RNA, as well as can be analyzed looking at each area. Modified mRNA
[0090] In some embodiments, the mRNA according to the present invention is unmodified or modified mRNA. A. Generally, the mRNA is modified to enhance stability. Modification of NA can include, for example, modification of nucleotides of RNA. The modified mRNA may contain, for example, backbone modifications, sugar modifications, or base modifications. In this embodiment, the mRNA contains purines (adenine (A), guanine (G)), or These include, but are not limited to, pyrimidines (thymine (T), cytosine (C), and uracil (U)). Naturally occurring nucleotides and / or nucleotide analogues (including modified nucleotides) From the 1-methyl-adenine, 2-methyl-adenine, 2-methylthio-N-6-isopropyl Isopentenyladenine, N6-methyladenine, N6-isopentenyladenine, 2-thio -cytosine, 3-methylcytosine, 4-acetylcytosine, 5-methylcytosine, 2,6 -Diaminopurine, 1-methylguanine, 2-methylguanine, 2,2-dimethylguanine 7-methylguanine, inosine, 1-methylinosine, pseudouracil (5-uracil uracil), dihydrouracil, 2-thio-uracil, 4-thio-uracil, 5-carboxymethyluracil 5-(carboxyhydroxymethyl)-uracil, 2-(methylaminomethyl)-uracil uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl -uracil, 5-methyl-2-thio-uracil, 5-methyluracil, N-uracil-5 -Oxyacetic acid methyl ester, 5-methylaminomethyl-uracil, 5-methoxyamino Methyl-2-thio-uracil, 5'-methoxycarbonylmethyluracil, 5-methoxy -Uracil, uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid (V ), 1-methylpseudouracil, queuosine, β-D-mannosyl-queuosine, Wybutoxocin, phosphoramidates, phosphorothioates, peptide nucleotides , methylphosphonic acid, 7-deazaguanosine, 5-methylcytosine and inosine, Can be synthesized as modified nucleotide analogs or derivatives of purines and pyrimidines The preparation of such analogs is described, for example, in US 4,373,071, S4,401,796, US4,415,732, US4,458,066, US4,5 00,707, US4,668,777, US4,973,679, US5,047,5 24, US5,132,418, US5,153,319, US5,262,530, and and U.S. Pat. No. 5,700,642, the disclosures of which are incorporated herein by reference in their entireties. Incorporated by reference.
[0091] In some embodiments, the mRNA may include RNA backbone modifications. Modification is a chemical modification of the phosphate backbone of the nucleotides contained in RNA. Typical backbone modifications are generally methylphosphonate, methylphosphoramidate, phosphonic acid, Phosphoramidate, phosphorothioate (e.g., cytidine 5'-O-(1-thiophosphate) Modifications include, but are not limited to, those selected from the group consisting of boranolic acid, guanidinium, and boranoic acid. It is not defined that other anionic, cationic, or neutral groups may be used to modify the phosphodiesterase. This means swapping the ter bonds.
[0092] In some embodiments, the mRNA may include sugar modifications. Exemplary sugar modifications include: 2'-Deoxy-2'-fluoro oligoribonucleotide (2'-fluoro-2'-deoxy Cycytidine 5'-triphosphate, 2'-fluoro-2'-deoxyuridine 5'-triphosphate) , 2'-deoxy-2'-deamine-oligoribonucleotide (2'-amino-2'-de Oxycytidine 5'-triphosphate, 2'-amino-2'-deoxyuridine 5'-triphosphate ), 2'-O-alkyl oligoribonucleotide, 2'-deoxy-2'-C-alkyl Oligoribonucleotide (2'-O-methylcytidine-5'-triphosphate, 2'-methyl Lysine 5'-triphosphate), 2'-C-alkyl oligoribonucleotides, and their (2 '-Aracytidine 5'-triphosphate, 2'-Arauidine 5'-triphosphate), is azidotriphosphate (2'-azido-2'-deoxycytidine 5'-triphosphate, isomers of 2'-deoxyuridine 5'-triphosphate; A chemical modification of the sugar of a nucleotide, including, but not limited to, a saccharide attachment.
[0093] In some embodiments, the mRNA comprises modifications of the bases of nucleotides (base modifications). A modified nucleotide that contains a base modification may also be referred to as a base-modified nucleotide. The base-modified nucleotide is 2-amino-6-chloropurine riboside 5'-triphosphate, 2-aminoadenosine 5'-triphosphate, 2-thiocytidine 5'-triphosphate, 2-thiouridine 4-thiouridine-5'-triphosphate, 5-aminoallylcytidine 5'-triphosphate '-triphosphate, 5-aminoallyl uridine 5'-triphosphate, 5-bromocytidine 5'-triphosphate 5-bromouridine 5'-triphosphate, 5-iodocytidine 5'-triphosphate, 5-iodo Uridine 5'-triphosphate, 5-methylcytidine-5'-triphosphate, 5-methyluridine 5 '-triphosphate, 6-azacytidine-5'-triphosphate, 6-azauridine 5'-triphosphate, 6-Chloropurine riboside 5'-triphosphate, 7-deazaadenosine 5'-triphosphate, 7- Deazaguanosine 5'-triphosphate, 8-azaadenosine 5'-triphosphate, 8-azidoadenosine Nosine 5'-triphosphate, benzimidazole riboside 5'-triphosphate, N1-methyladenosine Adenosine 5'-triphosphate, N1 methylguanosine 5'-triphosphate, N6 methyladenosine 5'-triphosphate '-triphosphate, O6 methylguanosine 5'-triphosphate, pseudouridine 5'-triphosphate , puromycin 5'-triphosphate or xanthosine 5'-triphosphate, but is not limited to Not done.
[0094] In general, mRNA synthesis involves the addition of a "cap" to the N-terminus (5') and a " The presence of a cap is the basis for the nucleotide sequence found in most eukaryotic cells. The presence of the "tail" is important for conferring resistance to exonuclease. Helps protect against creatine degradation. Cap Construction
[0095] In some embodiments, the mRNA comprises a 5' cap structure. The triplets are added as follows: First, the phosphate at the end of the RNA is attached to the 5' nucleotide. Then, one terminal phosphate group is removed and two terminal phosphates are released. guanosine triphosphate (GTP) is added to the terminal phosphate by aryltransferase , forming a 5'5'5 triphosphate bond. The 7-nitrogen of guanine is then methylated. An example of a cap structure is m7G(5')ppp( 5')A, G(5')ppp(5')A, and G(5')ppp(5')G. Not limited to:
[0096] The naturally occurring cap structure is a triphosphate bridge that protects the first transcribed nucleotide. Binds to the 5' end of m 7 G(5')ppp(5')N dinucleotide cap It contains 7-methylguanosine, where N is any nucleotide. In the nucleus, the cap is added enzymatically. The cap is added in the nucleus and then decomposed by the enzyme. It is catalyzed by a guanylyltransferase that caps the 5' end of RNA. The addition of a terminal nucleoside occurs immediately after the initiation of transcription. The terminal nucleoside is typically guanosine. It is in the opposite orientation to all other nucleotides, i.e., G(5')ppp(5')GpNpNp. It is.
[0097] The normal cap of mRNA produced by in vitro transcription is m 7 G(5') ppp(5')G, which is used to obtain RNA with a cap structure at the 5' end. In vitro transcription with T7 or SP6 RNA polymerase One method for in vitro synthesis of capped mRNA A common method is to use m 7 G(5')ppp(5')G(m 7 G pppG) is a preformed dinucleotide of the form
[0098] Currently, there are several synthetic dinucleotide caps available for use in in vitro translation experiments. The form is either an anti-reverse cap analog ("ARCA") or a modified ARCA. This is generally a modified cap where the 2' or 3' OH group is replaced with OCH3. It is an analogue.
[0099] Additional cap analogs include m 7 GpppG, m 7 GppA, m 7 GpppC; non-Methi dimethylated cap analogs (e.g., m 2 ,7 GpppG; trimethylated cap analogs (e.g., m 2,2,7 GpppG), Dimethylated symmetrical cap analogs (e.g., m 7 Gpppm 7 G), or Anne Chile reverse cap analogues (e.g., ARCA;m 7,2’Ome GpppG, m 72’ d GpppG, m 7,3’Ome GpppG, m 7,3’d GpppG and its four Phosphate derivatives). Jemielity, J. et al., “Novel 'anti-reversal e' cap analogs with superior translation al properties”, RNA, 9:1108-1122 (2003) thing).
[0100] In some embodiments, a suitable cap is first transferred by triphosphate crosslinking. Binds to the 5' end of the nucleotide 7 G(5')ppp(5')N is obtained, 7- Methylguanylic acid ("m7 G"), where N is any nucleotide. In the embodiments of the invention, 7 The preferred embodiment of the G-cap is m 7 G(5')p pp(5')G.
[0101] In some embodiments, the cap is a Cap 0 structure. The Cap 0 structure is The 2'-O-methyl residues of the riboses attached to bases 1 and 2 are missing. In an embodiment, the cap is a Cap1 structure. The Cap1 structure is a structure in which the base 2 is In some embodiments, the cap has a cap 2′-O-methyl residue. The cap 2 structure is a 2'-O-methyl residue attached to both base 2 and base 3. It has residue.
[0102] Various m 7 G-cap analogs are known in the art, many of which are commercially available. They are the same as those described above. 7 GpppG, ARCA3'-OCH3 and 2'- The same is true for OCH3 cap analogs (Jemielity, J. et al., RNA , 9:1108-1122 (2003). Additional examples of the key compounds used in the present invention include Chapp analogs are N7-benzylated dinucleoside tetraphosphate analogs (Grudzien, E. et al., RNA, 10: 1479-1487 (2004)), Thionate cap analogues (Grudzien-Nogalska, E., et al. , RNA, 13: 1745-1755 (2007)), US 8,093,367 and and tail cap analogs (biotinylated cap analogs) described in US 8,304,529. ), which are incorporated herein by reference. Tail Structure
[0103] In general, the presence of a "tail" serves to protect the mRNA from exonuclease degradation. The poly(A) tail is thought to stabilize natural messenger and synthetic sense RNA. Therefore, in certain embodiments, a long polyA tail is added to an mRNA molecule. The poly(A) tail can be used to synthesize a poly(A)-tailed RNA, which can then be used to make the RNA more stable. These may be added using art-recognized techniques. For example, long polyA tails may be added. The vectors were synthesized or transcribed in vitro using polyA polymerase. , can be added to RNA (Yokoe, et al. Nature Biotechnol. logy. 1996;14:1252-1256). The transcription vector also contains a long poly(A) tail. In addition, the polyA tail can be directly transcribed from the PCR product. Poly A can also be added to the 3' end of the sense RNA using RNA ligase. (Molecular Cloning A Laboratory Man ual,2nd Ed.,ed.by Sambrook,Fritsch and M. aniatis(Cold Spring Harbor Laboratory Pr ess:1991 edition).
[0104] In some embodiments, the mRNA comprises a 3' poly(A) tail structure. The length of the polyA tail is at least about 10, 50, 100, 200, 300, 400, or In some embodiments, the mRNA may be 500 nucleotides or 500 nucleotides. The polyA tail at the 3' end of the 200 adenosine nucleotides, about 10-150 adenosine nucleotides, about 10- 100 adenosine nucleotides, about 20 to 70 adenosine nucleotides, or about 2 0-60 adenosine nucleotides). In some embodiments, the mRNA The 3' poly(C) tail structure is generally about 10 ~200 cytosine nucleotides (e.g., about 10 to 150 cytosine nucleotides, about 10-100 cytosine nucleotides, about 20-70 cytosine nucleotides, about 20- 60 cytosine nucleotides, or about 10 to 40 cytosine nucleotides). The polyA tail may be added to or may replace the polyA tail. .
[0105] In some embodiments, the length of the polyA or polyC tail is It is regulated to control the stability of the mRNA molecule and thus the transcription of proteins. For example, the length of the poly(A) tail can affect the half-life of the sense mRNA molecule. The length of the mRNA can be adjusted to alter the level of resistance to nucleases. It is also possible to induce expression of a polynucleotide and / or production of a polypeptide in a target cell. It is also possible to control the elapsed time for the formation. 5' and 3' untranslated regions
[0106] In some embodiments, an mRNA includes 5' and / or 3' untranslated regions. In some embodiments, the 5' untranslated region may be used to regulate mRNA stability or translation, e.g. In some embodiments, the iron-responsive element is one or more elements that affect the iron-responsive element. In this case, the 5' untranslated region may be between about 50 and 500 nucleotides in length.
[0107] In some embodiments, the 3' untranslated region comprises one or more polyadenylation signals, A binding site or sites for proteins that affect the positional stability of the mRNA within the cell In some embodiments, the 3' untranslated region comprises a binding site for a microRNA of , may be between about 50 and 500 or more nucleotides in length.
[0108] Exemplary 3' and / or 5' UTR sequences are stable (e.g., globin, actin , GAPDH, tubulin, histones, or citric acid cycle enzymes) from mRNA molecules. This can increase the stability of the sense mRNA molecule. For example, the 5'UTR sequence may comprise a partial sequence of the CMV immediate early 1 (IE1) gene, or a fragment thereof, Improves nuclease resistance and / or improves half-life of polynucleotides. The human growth hormone (hGH) or a fragment thereof can be synthesized by the synthesis of a polynucleotide (e.g., mRNA). The inclusion of coding sequences in the 3' or untranslated regions of A) is also contemplated, and further polynucleotides In general, these modifications stabilize the octides compared to their unmodified counterparts. to improve the stability and / or pharmacokinetic properties (e.g., half-life) of the polynucleotide. and, for example, the resistance of the polynucleotide to in vivo nuclease degradation. This also includes modifications made to improve the Delivery Vehicles
[0109] According to the present invention, mRNA is expressed as naked RNA (unpackaged) or As used herein, a "delivery vehicle" refers to a pharmaceutical composition that is capable of delivering the pharmaceutical agent to the CNS. The terms "transfer carrier," "nanoparticle," or grammatically equivalent, are used interchangeably. .
[0110] In some embodiments, the mRNA may be delivered via a single delivery vehicle. In some embodiments, the mRNA is comprised of one or more species, each of which is of a different composition. According to various embodiments, a suitable delivery vehicle is a poly Ethyleneimine (PEI), lipid nanoparticles and liposomes, nanoliposomes, ceramide-containing Nanoliposomes, proteoliposomes, natural and synthetically derived exosomes, Natural, synthetic, and semi-synthetic layered bodies, nanoparticles, calcium silicate phosphor nanoparticles, phosphorus calcium oxide nanoparticles, silicon dioxide nanoparticles, nanocrystalline particles, semiconductor nanoparticles, poly (D-arginine), sol-gel, nano-dendrimers, starch-based delivery systems, micelles Emulsions, niosomes, multi-domain block polymers (vinyl polymers, poly Polypropylacrylic acid polymers, dynamic polyconjugates), dry powder formulations, plasmids, viruses Calcium phosphate nucleotides, aptamers, peptides and other vector types Examples of suitable carriers include, but are not limited to, polymeric carriers such as tethers. Liposomal Delivery Vehicles
[0111] In some embodiments, a suitable delivery vehicle is a liposome, such as, for example, a lipid nanoparticle. As used herein, a liposomal delivery vehicle, such as a lipid nanoparticle, is a An inner aqueous compartment usually separated from the outer medium by one or more bilayer membranes Liposomes are characterized as extremely small vesicles with a large internal volume. The bilayer membrane of a liposome is generally Both synthetic and naturally occurring lipids, including hydrophilic and hydrophobic regions, are used. Formed by amphiphilic molecules (Lasic, Trends Biotechnol., 16:307-321, 1998). In general, liposome delivery vehicles suitable for the present invention include (e.g., lipid nanoparticles or liposomes) may be composed of one or more different lipids and / or In some embodiments, the liposome is formed by combining a liposome with a polymer. The drug delivery vehicle (e.g., lipid nanoparticle or liposome) may be encapsulated in one or more cationic cationic lipid, one or more non-cationic / helper lipids, one or more collagen These include terol-based lipids, and / or one or more PEGylated lipids. Cationic lipids
[0112] In some embodiments, a suitable delivery vehicle comprises a cationic lipid. In this case, the term "cationic lipid" refers to the lipid that has a net pH at a selected pH, such as physiological pH. It refers to any of a number of lipid species that have a positive charge of 100 to 1500 mg / mL. Some cationic lipids, known as cationic lipids that can be used to deliver mRNA, are specifically targeted to this purpose. A variety of cationic (e.g., titratable) lipids have been described in the literature. Particularly preferred cationic surfactants for use in the compositions and methods of the present invention are The cyclic lipids are described in WO2010 / 053572 (and in particular in CI2-200, paragraphs [002 25], and WO2012 / 170930, both of which are The methods are incorporated by reference in their entirety. The substance is N-[l-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl Diammonium chloride, or "DOTMA" is used (Feigner et al. l.Proc.Nat'l Acad.Sci.84,7413(1987), US4, 897,355). DOTMA can be assembled alone or in combination with a neutral lipid, dioleoyltransferase. dihydrophosphatidyl-ethanolamine, or "DOPE," or other cations Cationic or non-cationic lipids can be attached to liposomal transfer carriers or lipid nanoparticles. , and the liposomes can be used to enhance delivery of the nucleic acid to target cells. Other suitable cationic lipids include, for example, 5-carboxyspermylglycine dioctadeca. Silamide, or "DOGS", 2,3-dioleoyloxy-N-[2(sperm N,N-dimethyl-l-propanaminium, or "DOSPA" (Behr et al.Proc.Nat.'l Acad.Sci. 86,6982 (1989) and US5,171,678, US5,334,761) , l,2-dioleoyl-3-dimethylammonium-propane, or "DODAP" , l,2-dioleoyl-3-trimethylammonium-propane, or "DOTAP ". A contemplated cationic lipid is l,2-distearyloxy-N,N-dimethyl -3-aminopropane, or "DSDMA", 1,2-dioleoyloxy-N,N -Dimethyl-3-aminopropane, or "DODMA", 1,2-diaminopropyl Di-N,N-dimethyl-3-aminopropane, or "DLinDMA", 1,2-diaminopropane Linoleyloxy-N,N-dimethyl-3-aminopropane, or "DLenDMA" ", N-dioleyl-N,N-dimethylammonium chloride, or "DODAC ", N,N-distearyl-N,N-dimethylammonium bromide, or "DDA B" N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N- Hydroxyethylammonium bromide, or "DMRIE", 3-dimethylamino -2-(cholest-5-en-3-beta-oxybutan-4-oxy)-1-(cis, cis,-9,12-octadecadienoxy)propane, or "CLinDMA", 2 -[5'-(cholest-5-en-3-beta-oxy)-3'-oxapentoxy]- 3-Dimethyl ll-(cis,cis-9',l-2'-octadecadienoxy)propane , or "CpLinDMA", N,N-dimethyl-3,4-dioleoyloxybenzamide Dioleylamine, or "DMOBA", 1,2-N,N'-dioleylcarbamyl-3- Dimethylaminopropane, or "DOcarbDAP", 2,3-Dimethylaminopropane Di-N,N-dimethylpropylamine, or "DLinDAP", 1,2-N,N' -Dilinoleylcarbamyl-3-dimethylaminopropane, or "DLincarb DAP", 1,2-Dilinoleylcarbamyl-3-dimethylaminopropane, or " DLinCDAP, 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]- Dioxolane, or "DLin--DMA", 2,2-Dilinoleyl-4-dimethyl Aminoethyl[1,3]-dioxolane, or "DLIN-K-XTC2-DMA" , and 2-(2,2-di((9Z,12Z)-octadeca-9,L2,dien-1-yl )-1,3-Dioxolan-4-yl)-N,N-dimethylethanamine (DLIN-K C2-DMA))(WO2010 / 042877, Semple et al., Nat ure Biotech. 28:172-176 (2010)), or This also includes mixtures of these (Heyes, J., et al., J Controlled Research release 107:276-287 (2005), Morrissey, DV., e. t al., Nat.Biotechnol.23(8):1003-1007(200 5), PCT Punlication WO2005 / 121348A1).
[0113] In some embodiments, the one or more positive ions present in such compositions The ionic lipid was XTC (2,2-diaminoethyl 1-4-dimethylaminoethyl 1-[1,3] -dioxolane), MC3 (((6Z,9Z,28Z,31Z)-heptatriaconta 6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate), ALNY-100 ((3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z ,12Z)-Octadeca-9,12-dienyl)tetrahydro-3aH-cyclopenta[ d][1,3]dioxol-5-amine)), NC98-5 (4,7,13-tris(3 -Oxo-3-(undecylamino)propyl)-N1,N16-diudecyl-4,7, 10,13-tetraazahexadecane-1,16-diamide), DODAP(1,2-di oleyl-3-dimethylammonium propane), HGT4003 (WO2012 / 17 0889, the teachings of which are incorporated herein by reference in their entirety), ICE (WO2 No. 011 / 068810, the teachings of which are incorporated herein by reference in their entirety. Be selected.
[0114] In certain embodiments, the compositions and methods of the present invention are directed to No. 6,117,468, which is incorporated herein by reference. Ionic cationic lipids, such as (15Z,18Z)-N,N-dimethyl-6-( 9Z,12Z)-Octadeca-9,12-diene-l-yl)tetracosa-15,18- Dien-1-amine (HGT5000), (15Z,18Z)-N,N-dimethyl-6- ((9Z,12Z)-Octadeca-9,12-dien-1-yl)tetracosa-4,15 ,18-triene-l-amine (HGT5001), and (15Z,18Z)-N,N- Dimethyl-6-((9Z,12Z)-octadeca-9,12-dien-1-yl)tetradecane Lipid nanoparticles, including cosa-5,15,18-trien-1-amine (HGT5002) Particles are used.
[0115] In some embodiments, the provided liposomes are On the same day as this application, a provisional application for "Lipid Formulation The positive results described in "S for Delivery of Messenger RNA" In some embodiments, the ionic lipids are both incorporated by reference. wherein the cationic lipid comprises a compound of formula I-c1-a: [ka] or a pharma- ceutically acceptable salt thereof, wherein: Each R 2 are independently hydrogen or C 1-3 is an alkyl group of the formula each q is independently 2 to 6; Each R' is independently hydrogen or C 1-3 is an alkyl group of the formula And each R L is independently C 8-12 is an alkyl group.
[0116] In some embodiments, each R 2 is independently hydrogen, methyl, or ethyl. In some embodiments, each R 2 are independently hydrogen or methyl. In the embodiment, each R 2 is hydrogen.
[0117] In some embodiments, each q is independently 3 to 6. and each q is independently 3 to 5. In some embodiments, each q is 4.
[0118] In some embodiments, each R' is independently hydrogen, methyl, or ethyl. In some embodiments, each R' is independently hydrogen or methyl. In embodiments, each R' is independently hydrogen.
[0119] In some embodiments, each R L is independently C 8-12 It is an alkyl group. In embodiments, each R L are independently nC 8-12 In some embodiments, In this state, each R L is independently C 9-11 In some embodiments, , each R Lare independently nC 9-11 In some embodiments, each R L is independently C 10 In some embodiments, each R L are independently n -C 10 It is an alkyl.
[0120] In some embodiments, each R 2 is independently hydrogen or methyl, and each q is independently each R' is independently hydrogen or methyl; and each R L is independently C8 -12 It is an alkyl.
[0121] In some embodiments, each R 2 is hydrogen, each q is independently 3 to 5, and each R ' is hydrogen, and each R L is independently C 8-12 It is an alkyl.
[0122] In some embodiments, each R 2 is hydrogen, each q is 4, and each R' is hydrogen. And each R L is independently C 8-12 It is an alkyl.
[0123] In some embodiments, the cationic lipid comprises a compound of formula Ig, [ka] or a pharma- ceutically acceptable salt thereof, wherein each R L is independently C 8-12 Alki In some embodiments, each R L are independently nC 8-12 Alkyl In some embodiments, each R Lis independently C 9-11 It is an alkyl group. In some embodiments, each R L are independently nC 9-11 It is an alkyl group. In the embodiment, each R L is independently C 10 In some embodiments, , each R L are independently nC 10 It is an alkyl.
[0124] In certain embodiments, the liposomes provided contain the cationic lipid cKK-E12, or or (3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine The structure of cKK-E12 is shown below. [ka]
[0125] In some embodiments, the preferred lipid nanoparticles of the present invention contain the following cationic Contains at least one of the following lipids: C12-200, DLin-KC2-DMA , cKK-E12, Re-1, DODMA, DODAP, HGT4003, ICE, XT C, DSPC, MC3, HGT5000, or HGT5001.
[0126] In some embodiments, the molar ratio of cationic lipids in the liposomes is about 1 Greater than 0%, greater than about 20%, greater than about 30%, or greater than about 40% Greater than about 50% greater than about 60% greater than about 70% greater than In some embodiments, the cationic lipid is in a molar ratio of about 1:1 to about 1:1. Approximately 30-50% (e.g., approximately 30-45%, approximately 30-40%, approximately 35-50%, approximately In some embodiments, the positive ion comprises about 35-45% or about 35-40%. The ionic lipid is about 30%, about 35%, about 40%, about 45%, or about 50% of the liposome by molar ratio. or approximately 50%. Non-cationic / helper lipids
[0127] In some embodiments, provided liposomes comprise one or more non-cationic As used herein, the term "non-cationic lipid" includes non-cationic (helper) lipids. As used herein, "anionic" refers to any neutral, zwitterionic, or anionic lipid. "Ionic lipids" are lipids that carry a net negative charge at selected pH levels, such as physiological pH. In some embodiments, the non-cationic lipid refers to a number of lipid species. i.e., the conditions under which the composition is assembled and / or administered. Non-cationic lipids are lipids that carry no net charge. Dioleoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DSPC), Dioleoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol ( DOPG), dipalmitoyl phosphatidylglycerol (DPPG), dioleoyl phosphatidyl Sphatidylethanolamine (DOPE), Palmitoyloleoylphosphatidylcholine Phosphorus (POPC), Palmitoyloleoyl-phosphatidylethanolamine (POP E) Dioleoylphosphatidylethanolamine-4-(N-maleimidomethyl)- Cyclohexane-l-carboxylate (DOPE-mal), dipalmitoyl phosphatase Dimyristoylethanolamine (DPPE), Dimyristoylphosphoethanolamine (DMP E), Distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-mono Nomethylpolyethylene, 16-O-dimethylpolyethylene, 18-1-transpolyethylene Len, l-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE) ), or mixtures thereof.
[0128] In some embodiments, suitable non-cationic (helper) lipids include one or more Phosphatidyl lipids of various kinds, such as phosphatidyl compounds (e.g., phosphatidylglycerol, cholor, phosphatidylcholine, phosphatidylserine, and phosphatidylethanol amines).
[0129] In some embodiments, suitable non-cationic (helper) lipids include one or more sphingolipids, e.g., sphingosine, ceramide, sphingomyelin, cerebrum These include glycerides, glycerides, and gangliosides.
[0130] In some embodiments, the non-cationic (helper) lipid is in the molar ratio of the liposome About 5% to about 90% (e.g., about 10-80%, 10-70%, 10 ~60%, 10~50%, 10~40%, 10~30%, or 10~20%) In some embodiments, the proportion of non-cationic (helper) lipids in the liposomes may be In this case, the molar ratio is greater than about 5%, greater than about 10%, or greater than about 15%. , about 20% or more, about 25% or more, about 30% or more, It may be greater than 35%, or greater than about 40%. Cholesterol-based lipids
[0131] In some embodiments, the liposomes provided contain one or more cholesterol-binding proteins. For example, suitable cholesterol-based cationic lipids include, for example, cholesterol terol, PEGylated cholesterol, DC-CHOi (N,N-dimethyl-N-ethyl 1,4-Bis(3-N-oleylamino-propyl) (Gao, et al. Biochem. Biophys. Res. Co mm.179,280(1991);Wolfetal.Bio Techniques 23,139 (1997), US 5,744,335), or ICE. In this embodiment, the cholesterol-based lipid is, in molar ratio, about 1:1 to the total lipid present in the liposome. The amount of the sieving agent may be about 2% to about 30%, or about 5% to about 20%. In this state, the proportion of cholesterol-based lipids in the lipid nanoparticles is more than 5% by molar ratio. , 10% more, 20% more, 30% more, or 40% more More is better. PEGylated lipids
[0132] In some embodiments, the lipid nanoparticles provided herein are provided with one or more PEGylated For example, polyethylene glycol (PEG)-modified phospholipids and N- Octanoyl-sphingosine-l-[succinyl(methoxypolyethylene glycol) Derivatized ceramides (PE-2000) (C8PEG-2000 ceramide) The use of derivatized lipids, such as G-CER, can be achieved by combining one or more cationic lipids, and in some embodiments, in admixture with other lipids contemplated by the present invention. In some embodiments, suitable PEGylated lipids have short acyl chains (e.g., C 14 or C 18 In some embodiments, the PEG-ceramide has the formula: Alternatively, the PEGylated lipid DSPE-PEG-maleimide-lectin may be used. Contemplated PEG-modified lipids include those having C6-C 20 Covalently bonded to lipids with alkyl chains of The specific polyethylene glycol chains include, but are not limited to, polyethylene glycol chains of 5 kDa or more in length. Without wishing to be bound by theory, this may be due to the fact that the addition of PEGylated lipids is a complex process. Circulating mRNA by preventing unwanted aggregation and facilitating delivery of liposomes encapsulating mRNA to target cells. It is contemplated that this may increase the life span.
[0133] In some embodiments, PEG-modified phospholipids and / or derivatized lipids is about 0% to about 20%, about 0% to about 20%, or ... 15%, 0% to 10%, 1% to 10%, 1% to 8%, 1% to 6%, 1 % to about 5%, about 2% to about 10%, or about 4% to about 10%. The ratio of PEG-modified phospholipid and / or derivatized lipid is, in terms of molar ratio, , about 20%, about 15%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, or about 1% or less In some embodiments, PEG-modified phospholipids and / or derivatized lipids are The molar ratio of the lipids in the liposomes was about 1%, about 2%, and about 3%. %, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, or It may be about 20% or more. polymer
[0134] In some embodiments, a suitable delivery vehicle is one that uses a polymer as the carrier alone. or in combination with other carriers, including various lipids as described herein. Thus, in some embodiments, the liposome delivery vehicle is As used herein, the term also includes polymers that contain nanoparticles. Suitable polymers include, for example: Polyacrylate, polyalkyl cyanoacrylate, polylactide, polylactide-poly Liglycolide copolymer, polycaprolactone, dextran, albumin, gelatin, Alginate, collagen, chitosan, cyclodextrin, protamine, PEGylated protamine These may include polyethyleneimine, PLL, PEGylated PLL and polyethyleneimine (PEI). When EI is present, it is linear or branched, with a molecular weight in the range of 10-40 kDa. It may be PEI, for example 25 kDa branched PEI (Sigma #408727).
[0135] In various embodiments, suitable delivery vehicles (e.g., lipid nanoparticles) are described herein. By combining one or more lipid and / or polymer components, For example, lipid nanoparticles can be prepared using C12-200, sphingomyelin, DOP, etc. E, cholesterol, and DMGPEG; or C12-200, DOPE, cholesterol or cKK-E12, DOPE, cholesterol, and and DMG-PEG2K; or cKK-E12, sphingomyelin, DOPE, cholesterol terol, and DMG-PEG2K; or HGT5001, DOPE, cholesterol , and DMG-PEG2K; or HGT4003, DOPE, cholesterol, and D MG-PEG2K; or DLinKC2DMA, DOPE, cholesterol and DMG -PEG2K; or ICE, DOPE, cholesterol and DMG-PEG2K; or or DODMA, DOPE, cholesterol and DMG-PEG2K; Sphingomyelin, DOPE, cholesterol, and DMG-PEG2K; or Re -1, DOPE, cholesterol, DMG-PEG2K; or cKK-EE12, DO PE, cholesterol, DMG-PEG2K and / or DSPE-PEG-maleimide -Can be prepared with a mixture of lectins.
[0136] In various embodiments, the cationic lipid, the non-cationic lipid, the cholesterol, and / or the Alternatively, the PEG-modified lipids can be combined in various relative molar ratios. cationic lipids (e.g., cKK-E12, C12-200, etc.), non-cationic lipids (e.g., DOPE, sphingomyelin, etc.) and cholesterol-based lipids (e.g., cholesterol The ratio of the PEG-containing lipid (e.g., DMG-PEG2K) to the PEG-containing lipid (e.g., DMG-PEG2K) is The ratios may be between about 30-60:25-35:20-30:1-15, respectively. In some embodiments, cationic lipids (e.g., cKK-E12, C12-200, etc. ) non-cationic lipids (e.g., DOPE, sphingomyelin, etc.) and cholesterol. cholesterol) and PEGylated lipids (e.g., DMG-PE G2K) are approximately 40:30:20:10, respectively. In an embodiment, cationic lipids (e.g., cKK-E12, C12-200, etc.) , non-cationic lipids (e.g., DOPE, sphingomyelin, etc.), and cholesterol A lipid (e.g., cholesterol) and a PEGylated lipid (e.g., DMG-PEG2 K) are approximately 40:30:25:5, respectively. In this embodiment, cationic lipids (e.g., cKK-E12, C12-200, etc.) are used in combination with non-cationic lipids. Ionic lipids (e.g., DOPE, sphingomyelin, etc.) and cholesterol-based lipids (e.g., cholesterol) and a PEGylated lipid (e.g., DMG-PEG2K). The ratio of the amines to the amines is approximately 40:32:25:3, respectively. In this case, cationic lipids (e.g., cKK-E12, C12-200, etc.) are used in place of non-cationic lipids. Lipids based on cholesterol (e.g., DOPE, sphingomyelin, etc.) and cholesterol-based lipids (e.g., For example, cholesterol) and PEGylated lipids (e.g., DMG-PEG2K) The ratios are approximately 50:25:20:5, respectively. Preparation of lipid nanoparticles
[0137] The delivery carriers used in the present invention, such as lipid nanoparticles, can be prepared using various techniques currently known in the art. Multilamellar liposomes (MLVs) can be prepared by conventional techniques. For example, a lipid of choice may be applied to the inner walls of a suitable container or vessel by dissolving the lipid in a suitable solvent. After depositing the material, the solvent is evaporated or spray dried to remove the material from the container. The aqueous phase is then added to the vessel while still being vortexed, leaving a thin film on the side. Unilamellar liposomes (ULVs) are then formed by homogenizing, ultrafiltration, and dissolving the multilamellar liposomes. Unilamellar liposomes can be formed by sonication or extrusion. It may be formed by subtractive techniques.
[0138] In a particular embodiment of the present invention, the composition of the present invention comprises a transfer carrier, The mRNA is associated with both surfaces of the transcription carrier and is packaged within the same transcription carrier. During preparation of the composition, cationic lipids associate with mRNA via electrostatic interactions. It can be done.
[0139] The bilayer membrane of the liposome is composed of an amphiphilic polymer and a surface active substance (e.g., polymersomes). , niosomes, etc.) Binding of the desired mRNA to liposomes The process is often referred to as "loading". A typical method is described by Lasic, et al. , FEBS Lett., 312:255-258, 1992, and The nucleic acid incorporated in the liposome is a nucleic acid that is capable of binding to the liposome bipartite. It may be located completely or partially in the intraliposomal space within the liposome membrane, or it may be located within the liposome. The incorporation of nucleic acids into liposomes is referred to herein as "encapsulation." " in which the nucleic acid is contained entirely within the interior space of the liposome. The purpose of incorporating mRNA into a transcriptional carrier such as a transcription factor is to synthesize nucleic acids and / or systems, or Contains enzymes or chemicals that degrade receptors, causing rapid acid secretion. This is often to protect the nucleic acid from the environment. The delivery vehicle may enhance the stability of the mRNA contained therein and / or enhance the targeting of the mRNA. This facilitates delivery of mRNA to targeted CNS cells or biological tissues.
[0140] Suitable liposome delivery vehicles according to the present invention may be made in a variety of sizes. In this embodiment, the size of the liposome is the length of the largest diameter of the liposome particle. In some embodiments, suitable liposome delivery vehicles have a diameter of about 250 nm or less. (For example, about 225 nm, 200 nm, 175 nm, 150 nm, 125 nm, 100 nm m, 90nm, 80nm, 70nm, 60nm, 50nm, or 40nm or less) In some embodiments, a suitable liposome delivery vehicle has a length of about 40 to 10 0 nm (for example, about 40 to 90 nm, about 40 to 80 nm, about 40 to 70 nm, about 40 to 6 0nm, approx. 40~50nm, approx. 50~100nm, approx. 50~90nm, approx. 50~80nm , about 50-70nm, about 50-60nm, about 60-100nm, about 60-90nm, about 6 0~80nm, approx. 60~70nm, approx. 70~100nm, approx. 70~90nm, approx. 70~8 0 nm, about 80-100 nm, about 80-90 nm, or about 90-100 nm) It has a range of sizes.
[0141] Various methods known in the art can be used to size the assembly of liposomal transcription carriers. One such sizing method is described in U.S. Pat. No. 4,737,323. and is incorporated herein by reference. By sonicating the liposome suspension, the desired small ULVs can be achieved. Homogenization can result in the generation of large liposomes that undergo size reduction. Another method is to use shear energy to fragment the mixture into fine particles. In the first step, MLVs are homogenized using standard emulsion homogenizers until they reach the selected liposome size. The size of the liposome carrier is determined by the method described in Bloomfield, Ann. Rev. Biophys. Bioeng., 10:421-150 (1981) This can be determined by quasi-elastic light scattering (QELS) as described in The standard liposome diameter was determined by subjecting the formed liposomes to ultrasonic treatment. To achieve efficient liposome synthesis, intermittent ultrafiltration is required. Sonication cycles may be alternated with QELS assessments. CNS delivery
[0142] As described herein, mRNA or an mRNA containing a delivery vehicle (e.g., RNA-loaded lipid nanoparticles are suitable for CNS delivery. In this study, mRNA-loaded lipid nanoparticles were administered intraparenchymal, intracerebral, and intracerebroventricularly (ICV) ), intrathecal (e.g., IT-lumbar, IT-cisternomagna), and into the CNS and / or CSF By a variety of techniques and routes, including any other technique and route of direct or indirect injection. , and can be delivered to the CNS. intrathecal delivery
[0143] In some embodiments, the mRNA-loaded lipid nanoparticles are It is delivered to the CNS by injection into the cerebrospinal fluid (CSF) of the body. In this study, intrathecal administration was used to inject mRNA or nanoparticles loaded with mRNA into the CSF. As used herein, intrathecal administration (also called intrathecal injection) refers to refers to an injection into the spinal canal (the intrathecal space that surrounds the spinal cord). Burr hole, cisterna magna, or lumbar puncture A variety of techniques may be used, including, but not limited to, lateral ventricular injection, via the ventricle or via a catheter. A typical method is Lazorthes et al. Advances in D rug Delivery Systems and Applications in Neurosurgery, 143-192, and Omaya et al., Can cer Drug Delivery, 1:169-179, The contents are incorporated by reference.
[0144] According to the present invention, the mRNA or nanoparticles loaded with mRNA surround the spinal canal. In some embodiments, the mRNA or mRNA may be injected into any area. The loaded nanoparticles are injected into the lumbar region, or into the cisterna magna, or into the ventricular space of the brain. As used herein, the term "lumbar region" or "lumbar area" refers to The area between the third and fourth lumbar vertebrae (lower back), more generally the L2-S1 region of the spine. Generally, intrathecal injection via the lumbar or lumbar region is referred to as “lumbar IT delivery” or “ It is also called “lumbar IT administration.” The term “cisterna magna” refers to the opening between the skull and the upper spine through which the In general, intrathecal injection via the cisterna magna is called "cisternal delivery." The term "ventricle" refers to a cavity within the brain that is continuous with the central canal of the spinal cord. Injection via the ventricular space is referred to as intracerebroventricular (ICV) delivery.
[0145] In some embodiments, "intrathecal administration" or "intrathecal delivery" according to the present invention refers to, e.g. between the third and fourth lumbar vertebrae (lower back), and more generally, to the L2-S1 region of the spine. This refers to lumbar IT administration or delivery.
[0146] In some embodiments, intrathecal administration is by lumbar puncture (i.e., slow bolus) or porcine. The administration can be via either a catheter delivery system (i.e., infusion or bolus). In some embodiments, the catheter is inserted between the lumbar lamina and the tip is inserted into the thecal space. It is penetrated to the desired level (usually L3-L4). Administration
[0147] The present invention relates to the treatment of mRNA or mRNA-loaded nanoparticles as described herein. Single and multiple administrations of therapeutically effective amounts are contemplated. The nanoparticles may be administered for a period of time depending on the nature, severity, and extent of the CNS disease or condition of the subject. In some embodiments, the mRNA or mRNA-loaded nucleic acid may be administered at intervals. The therapeutically effective amount of nanoparticles may be administered at regular intervals (e.g., once a year, once every six months, once every five months, Once every 3 months, once every 2 months, once every month, once every month, once every 2 weeks, The drug may be administered intrathecally on a regular basis (weekly, daily or continuously).
[0148] In some embodiments, the CNS disorder is associated with a psychological condition. In embodiments, intrathecal administration is preferred over other routes of administration (e.g., intravenous, subcutaneous, intramuscular, intestinal, etc. It may be used in conjunction with topical, transdermal, or transmucosal (e.g., oral or nasal) do.
[0149] As used herein, the term "therapeutically effective amount" refers primarily to the amount of a pharmaceutical composition of the present invention. Generally, a therapeutically effective amount is determined based on the total amount of mRNA contained in the sample. A meaningful benefit to the patient (e.g., treating, regulating, curing, or preventing the underlying disease or condition) For example, a therapeutically effective amount is sufficient to achieve a therapeutically effective amount of may be in an amount sufficient to achieve the desired therapeutic and / or prophylactic effect. The amount of mRNA to be administered to a subject in need thereof will depend on the characteristics of the subject. Such characteristics include the subject's symptoms, severity of the disease, general health, age, sex, and weight. Those skilled in the art will be able to readily determine appropriate dosages depending on these and other relevant factors. In addition, objective and subjective testing may optionally be used to identify optimal dosage ranges. It can be done.
[0150] In some embodiments, the therapeutically effective amount is about 0.001 mg to 10 mg per kg of body weight. mg, about 0.005 mg to about 10 mg per kg of body weight, about 0.005 mg to about 10 mg per kg of body weight 0.01mg to 10mg, 0.01mg to 9mg per kg of body weight, 0.01mg to 9mg per kg of body weight Approximately 0.01mg to 8mg per gram, approximately 0.01mg to 7mg per kg of body weight , about 0.01mg to about 6mg per kg of body weight, about 0.01mg per kg of body weight ~5mg, ~0.01mg to ~4mg per kg of body weight, ~0.01mg to ~4mg per kg of body weight 0.01mg to 3mg, 0.01mg to 2mg per kg of body weight, 0.01mg to 2mg per kg of body weight Approximately 0.01mg to 1mg per kg, approximately 0.01mg to 0.5mg per kg of body weight mg, about 0.1 mg to about 10 mg per kg of body weight, about 0.1 mg to about 10 mg per kg of body weight mg to about 5 mg, about 0.5 mg to about 10 mg per kg of body weight, or The range is about 0.5 mg to about 5 mg per gram.
[0151] In some embodiments, the therapeutically effective amount is about 0.001 mg / kg brain weight to about 0.001 mg / kg brain weight. Up to 100 mg per kg of brain weight, approximately 0.001 mg to 90 mg per kg of brain weight Approximately 0.001mg to 80mg per kg of brain weight, approximately 0.001mg to 70mg per kg of brain weight Up to about 0.001 mg / kg brain weight to 60 mg / kg brain weight. 0.001mg to 50mg, approximately 0.001mg to 40mg per kg of brain weight, Approximately 0.001 mg to 30 mg per kg of weight, approximately 0.001 mg per kg of brain weight ~20 mg per kg of brain weight, approximately 0.001 mg to 10 mg per kg of brain weight Approximately 0.001mg to 5mg per kg of brain weight, approximately 0.001mg to 1mg per kg of brain weight , from about 0.01 mg to 100 mg per kg of brain weight, and from about 0.05 mg to 100 mg per kg of brain weight mg to 100 mg, approximately 0.1 mg to 100 mg per kg of brain weight, or The range is approximately 0.5 mg to 100 mg per kg.
[0152] Those skilled in the art will appreciate that brain weight and body weight may be correlated (Dekaban A S.“Changes in brain weights during the s. pan of human life: relation of brain wei ghts to body heights and body weights,”A nn Neurol 1978; 4:345-56). Thus, in some embodiments In this case, the dosage can be converted as shown in Table 5. [Table 5] Delivery to neurons and other cell types in the brain and / or spinal cord
[0153] The method of the present invention is directed to the development of a method for the detection of inflammatory cytokines in various neurons and other cell types in the brain and / or spinal cord. In some embodiments, the delivery of an mRNA encoding a therapeutic protein is The mRNA is expressed in neurons, glial cells, perivascular cells, and / or meningeal cells. In particular, the method of the present invention delivers the medicament to various cells in the brain, including, but not limited to, in various neurons and other cell types affected by CNS diseases and / or defects. or the defective proteins associated with CNS diseases are expressed in various neuronal In some embodiments, the present invention provides delivery of mRNA in mammalian cells and other cell types. The method may be used, for example, in a patient suffering from or susceptible to a lysosomal storage disease. detectable or abnormally large amounts of enzyme groups stored in the lysosomes of cells of biological tissues This results in mRNA delivery in various neurons and other cell types within the CNS where the In some embodiments, the method of the present invention provides a method for treating a disease-related pathology. Delivery of mRNA to various neurons and other cell types that exhibit symptoms or characteristics. For example, mRNA can be used to treat psychodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, etc.). or those neurons or non-neuronal cells associated with the disorders described herein (such as rheumatoid arthritis, ... and Huntington's disease); Motor neuron diseases (e.g., amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PL S), pseudobulbar palsy, hereditary spastic paraplegia, progressive muscular atrophy (PMA), progressive bulbar palsy (PB P), distal hereditary motor neuropathy, and spinal muscular atrophy) Neurons or other tissues that deteriorate, degenerate, or undergo apoptosis, such as The antibodies can be delivered to other cell types.
[0154] In some embodiments, the mRNA is expressed in neurons and / or non-neurons located in the brain. In some embodiments, the mRNA is delivered to a neuronal cell in the spinal cord. In some embodiments, the antibody is delivered to neurons and / or non-neuronal cells. In some embodiments, the mRNA is delivered to a motor neuron. A is delivered to upper and / or lower motor neurons. In an embodiment, the motor neurons are located in the anterior horn and / or dorsal root ganglion of the spinal cord. is doing.
[0155] In some embodiments, the mRNA is expressed in various neurons in the brain and / or spinal cord. and other cell types. In some embodiments, the mRNA is delivered intracellularly. In some embodiments, mRNA delivery according to the present invention is performed in the axon of the neuron. is the intracellular expression of the protein encoded by the mRNA in the cytosol of neurons. In some embodiments, mRNA delivery according to the present invention results in neuronal expression. Intracellular compartments of the protein, such as lysosomes, mitochondria, transmembrane, etc. This results in intracellular expression of the protein encoded by the mRNA. In one embodiment, the mRNA delivery according to the present invention is carried out by directing the delivery of the mRNA and the encoded protein to the neuron. This results in the intracellular expression of proteins and their extracellular secretion from neurons.
[0156] Further exemplary neurons and other cell types in the brain and / or spinal cord are described below as examples. As shown. brain
[0157] Generally, the methods of the present invention involve the detection of neurons and other cell types in various regions of the brain. These can be used to deliver mRNA and the encoded protein to the brain. , can be divided into separate regions, layers, and biological cells. For example, the biological tissue of the meninges includes the brain. The meninges are a membranous system that surrounds the central nervous system. They contain three layers: the dura mater, the arachnoid mater, and the pia mater. In general, the primary function of the meninges and cerebrospinal fluid is to protect the central nervous system. In some embodiments, the mRNA and encoded protein is derived from a type of meninges or Delivery to neurons or non-neuronal cells in multiple layers.
[0158] The brain has three divisions, including the cerebrum, cerebellum, and brain stem. It sits above most other brain structures. The cerebral hemispheres, which are located in the brain, are covered by the cortex. Below the cerebrum lies the brain stem, which The cerebrum is like a stem on which the cerebrum is attached. Behind it is the cerebellum.
[0159] Located near the midline of the brain and above the midbrain, the diencephalon is made up of the thalamus, posterior thalamus, hypothalamus, and epithalamus. The midbrain contains the central nervous system, the ventral thalamus and the ventral tectum. midbrain), which includes the optic tectum, tegmentum, aqueduct, cerebral peduncle, red nucleus, and third cerebral cortex. The midbrain contains the neural nuclei involved in vision, hearing, motor control, sleep / wakefulness, vigilance, and temperature regulation. To connect.
[0160] In some embodiments, the mRNA and encoded protein is derived from a type of cerebellum or The therapeutic agent is delivered to neurons and / or non-neuronal cells in multiple biological tissues. In this embodiment, the target cerebellar biological tissue or tissues are selected from the group consisting of molecular layer biological tissue, protozoan biological tissue, and cerebellar tissue. It consists of the biological tissue of the Lukinje cell layer, the biological tissue of the granule cell layer, the cerebellar peduncle, and a combination of these. In some embodiments, the mRNA and the encoded protein are selected from the group consisting of: The tissue is composed of the Purkinje cell layer biological tissue, the granule cell layer biological tissue, and the deep cerebellar white matter biological tissue ( (e.g., deep to the granule cell layer), and the biological tissue of the deep cerebellar nuclei. The therapeutic agent is delivered to one or more deep tissues of the cerebellum that are not otherwise exposed to the cerebellum.
[0161] In some embodiments, the mRNA and encoded protein is derived from a brainstem or is delivered to multiple biological tissues.
[0162] In some embodiments, the mRNA and encoded protein is derived from grey matter, white matter, Periventricular area, pia mater-arachnoid mater, meninges, neocortex, cerebellum, deep tissues of the cerebral cortex, molecular layer, caudate nucleus / putamen region, midbrain, pons or deep regions of the medulla oblongata, and combinations thereof In some embodiments, the mRNA and The encoded protein is delivered to oligodendrocytes in the deep white matter. Spinal cord
[0163] In some embodiments, the method of the present invention provides a method for the treatment of neuronal dysfunction in various regions of the spinal cord. Used to deliver mRNA and the encoded protein to mammalian cells and other cell types. Generally, regions of the spinal cord or biological tissue may be differentiated based on the depth of the biological tissue. For example, spinal cord tissue can be characterized as superficial or superficial tissue, mid-deep tissue, and / or or may be characterized as deep tissue.
[0164] In some embodiments, the mRNA and encoded protein is derived from a spinal cord or The is delivered to multiple superficial or superficial tissues. In some embodiments, the is delivered to a spinal cord target. Superficial or superficial tissue includes the pia mater and / or white matter tracts.
[0165] In some embodiments, the mRNA and encoded protein is derived from a spinal cord or is delivered to multiple deep tissues. In some embodiments, the target deep tissue of the spinal cord is , containing spinal cord grey matter and / or ependymal cells.
[0166] The present invention will be more fully understood by reference to the following examples. While they should not be construed as limiting the scope of the invention, all literature citations are incorporated herein by reference. is incorporated by reference. EXAMPLES
[0167] Example 1 Formulations and messenger RNA substances This example illustrates the use of a typical lysosomal RNA for efficient delivery and expression of mRNA in the CNS. Generally, the formulations described herein are capable of encapsulating a variety of nucleic acid-based agents. One or more cationic lipids, neutral lipids, and cholesterol, designed to and / or contain multi-component lipid mixtures with varying ratios of PEGylated lipids. Messenger RNA material
[0168] Codon-optimized human survival motor neuron-1 (hSMN-1) messenger RNA was Synthesized by in vitro transcription from gene-encoding plasmid DNA templates This is followed by the addition of the 5' cap structure (Cap 1) (Fechter, P.; Brow nlee,GG“Recognition of mRNA cap struct ures by viral and cellular proteins”J.Ge n.Virology 2005,86,1239-1249) and gel electrophoresis A 3' poly(A) tail of approximately 250 nucleotides in length was added to each mRNA. The 5' and 3' untranslated regions present in the composition are represented by X and Y, respectively, and are defined as described. It is justified. Survival motor neuron (hSMN-1) mRNA X-SEQ ID NO:3-Y 5' and 3' UTR sequences X(5'UTR sequence)= GGACAGAUCGCCUGGAGACGCCAUCCACGCUGUUUUGAC CUCCAUAGAAGACACCGGGACCGAUCCAGCCUCCGCGGCC GGGAACGGUGCAUUGGAACGCGGAUUCCCCGUGCCAAGAG UGACUCACCGUCCUUGACACG (SEQ ID NO: 7) Y(3'UTR sequence)= CGGGUGGCAUCCCUGUGACCCCUCCCCAGUGCCUCUCCU GGCCCUGGAAGUUGCCACUCCAGUGCCCACCAGCCUUGUC CUAAUAAAAUUAAGUUGCAUCAAGCU (SEQ ID NO: 8) or GGGUGGCAUCCCUGUGACCCCUCCCCAGUGCCUCUCCUG GCCCUGGAAGUUGCCACUCCAGUGCCCACCAGCCUUGUCC UAAUAAAAUUAAGUUGCAUCAAAGCU (SEQ ID NO: 9)
[0169] For example, the codon-optimized human survival motor neuron-1 (hSMN-1) messenger RNA A contains the following, GGACAGAUCGCCUGGAGACGCCAUCCACGCUGUUUUGAC CUCCAUAGAAGACACCGGGACCGAUCCAGCCUCCGCGGCC GGGAACGGUGCAUUGGAACGCGGAUUCCCCGUGCCAAGAG UGACUCACCGUCCUUGACACGAUGGCCAUGAGCAGCGGAG GCAGCGGCGGAGGAGUGCCCGAGCAGGAGGACAGCGUGCU GUUCAGGAGAGGCACCGGCCAGAGCGAUGACAGCGAUAUC UGGGACGAUACCGCUCUGAUCAAGGCCUACGACAAGGCCG UGGCCAGCUUCAAGCACGCCCUGAAAAACGGCGACAUCUG CGAGACCAGCGGCAAGCCCAAGACAACCCCCAAGAGAAAG CCCGCCAAGAAGAAUAAGAGCCAGAAAAAGAACACCGCCG CCAGCCUGCAGCAGUGGAAGGUGGGCGACAAGUGCAGCGC CAUCUGGAGCGAGGACGGCUGCAUCUACCCCGCCACCAUC GCCAGCAUCGACUUCAAGAGAGAGACCUGCGUGGUCGUGU ACACCGGCUACGGCAACAGAGAGGAGCAGAACCUGAGCGA CCUGCUGAGCCCCAUUUGUGAGGUGGCCAAUAACAUCGAA CAGAACGCCCAGGAGAACGAGAAUGAAAGCCAGGUGAGCA CCGACGAGAGCGAGAACAGCAGAUCUCCUGGCAACAAGAG CGACAACAUCAAGCCUAAGUCUGCCCCUUGGAACAGCUUC CUGCCCCCUCCUCCACCCAUGCCCGGACCCAGACUGGGAC CCGGAAAACCUGGCCUGAAGUUCAACGGACCACCUCCCCC UCCACCUCCUCCCCCACCUCAUCUCCUGAGCUGCUGGCUG CCACCCUUCCCCAGCGGACCCCCUAUCAUCCCACCACCCC CUCCCAUCUGCCCCGACAGCCUGGACGACGCCGAUGCCCU GGGCAGCAUGCUGAUCAGCUGGUACAUGAGCGGCUACCAC ACAGGAUACUACAUGGGCUUCAGACAGAACCAGAAGGAGG GCAGAUGCUCCCACUCCCUGAACUGACGGGUGGCAUCCCU GUGACCCCUCCCCAGUGCCUCUCCUGGCCCUGGAAGUUGC CACUCCAGUGCCCACCAGCCUUGUCCUAAUAAAAUUAAGU UGCAUCAAGCU(SEQ ID NO:10) Or, the codon-optimized human survival motor neuron-1 (hSMN-1) messenger R NA is GGACAGAUCGCCUGGAGACGCCAUCCACGCUGUUUUGAC CUCCAUAGAAGACACCGGGACCGAUCCAGCCUCCGCGGCC GGGAACGGUGCAUUGGAACGCGGAUUCCCCGUGCCAAGAG UGACUCACCGUCCUUGACACGAUGGCCAUGAGCAGCGGAG GCAGCGGCGGAGGAGUGCCCGAGCAGGAGGACAGCGUGCU GUUCAGGAGAGGCACCGGCCAGAGCGAUGACAGCGAUAUC UGGGACGAUACCGCUCUGAUCAAGGCCUACGACAAGGCCG UGGCCAGCUUCAAGCACGCCCUGAAAAACGGCGACAUCUG CGAGACCAGCGGCAAGCCCAAGACAACCCCCAAGAGAAAG CCCGCCAAGAAGAAUAAGAGCCAGAAAAAGAACACCGCCG CCAGCCUGCAGCAGUGGAAGGUGGGCGACAAGUGCAGCGC CAUCUGGAGCGAGGACGGCUGCAUCUACCCCGCCACCAUC GCCAGCAUCGACUUCAAGAGAGAGACCUGCGUGGUCGUGU ACACCGGCUACGGCAACAGAGAGGAGCAGAACCUGAGCGA CCUGCUGAGCCCCAUUUGUGAGGUGGCCAAUAACAUCGAA CAGAACGCCCAGGAGAACGAGAAUGAAAGCCAGGUGAGCA CCGACGAGAGCGAGAACAGCAGAUCUCCUGGCAACAAGAG CGACAACAUCAAGCCUAAGUCUGCCCCUUGGAACAGCUUC CUGCCCCCUCCUCCACCCAUGCCCGGACCCAGACUGGGAC CCGGAAAACCUGGCCUGAAGUUCAACGGACCACCUCCCCC UCCACCUCCUCCCCCACCUCAUCUCCUGAGCUGCUGGCUG CCACCCUUCCCCAGCGGACCCCCUAUCAUCCCACCACCCC CUCCCAUCUGCCCCGACAGCCUGGACGACGCCGAUGCCCU GGGCAGCAUGCUGAUCAGCUGGUACAUGAGCGGCUACCAC ACAGGAUACUACAUGGGCUUCAGACAGAACCAGAAGGAGG GCAGAUGCUCCCACUCCCUGAACUGAGGGUGGCAUCCCUG UGACCCCUCCCCAGUGCCUCUCCUGGCCCUGGAAGUUGCC ACUCCAGUGCCCACCAGCCUUGUCCUAAUAAAAUUAAGUU Contains GCAUCAAAGCU (sequence number 11). Typical Manufacturing Procedure
[0170] Lipid nanoparticles (LNPs) are formed by a standard ethanol injection method (Ponsa ,M.;Foradada,M.;Estelrich,J.“Liposomes o btained by the ethanol injection method” Int. J. Pharm. 1993, 95, 51-56). For various lipid components A 50 mg / ml stock solution in ethanol was prepared and stored at -20°C. In preparing each of the exemplary formulations listed, the indicated lipid components were added to an ethanol solution, and the resulting A final volume of 3 ml of ethanol was prepared to achieve a constant final concentration and molar ratio. N-1 mRNA in aqueous buffer (10 mM citric acid / 150 mM NaCl, pH 4.5 ) were prepared from 1 mg / ml stock solutions. The lipid solutions were then infused either manually or with a syringe pump. Then, quickly inject the mixture into the aqueous mRNA solution and shake to bring the final concentration to 20% ethanol. The resulting nanoparticle suspension was filtered and diluted with 1x PBS (pH 7.4). The SMN-1 mRNA concentrate was then dialyzed, concentrated, and stored at 2-8°C. was measured by Ribogreen® (Invitrogen) assay. In the inclusion of A, the presence or absence of 0.1% Triton®-X100 was examined. The particle size was determined by performing an ibogreen analysis. S) and zeta potential were measured using Malvern The determination was made using a Zetasizer instrument. [Table 6-1] [Table 6-2] [Table 6-3] Example 2 Intrathecal administration of mRNA-loaded liposomal nanoparticles
[0171] This example illustrates an exemplary method for intrathecal administration of liposomal nanoparticles loaded with mRNA. and methods for analyzing mRNA delivered into neurons.
[0172] All studies were performed on either rats or mice that were approximately 6–8 weeks old at the start of each experiment. At the start of the experiment, each animal was anesthetized with isoflurane (1–3% concentration) via inhalation. Once anesthetized, each animal was anesthetized at the correct injection site (L4-L5 or L5-L6) on the body. The hair was shaved off. Following needle insertion, a reflexive flick of the tail indicates puncture of the dura. Each animal received one of the test preparations listed in Table 6. One of the animals received a single bolus intrathecal injection. All animals were sacrificed 24 hours after injection. The patient was sacrificed and perfused with saline. Isolation of organ tissue for analysis
[0173] All animals were subjected to whole brain and spinal cord removal. The brains were cut longitudinally and separated into one set per animal. The whole spinal cord was then placed in a woven cassette. The whole spinal cord was then transferred to a 70% tissue grade alcohol solution for 1 In a 15 ml tube containing 0% neutral buffered formalin (NBF), the specimen was incubated for 24 hours or more. Each spinal cord sample was cut into the cervical, thoracic, and lumbar regions. The spinal cord was cut in half and each half was used for processing at each site (cervical, thoracic, and lumbar). All three cassettes were placed in separate cassettes, one paraffin block per animal. When applicable, portions of the brain and spinal cord were flash frozen and stored at -80°C. Piped. hSMN-1 Western blot analysis
[0174] Following standard Western blot procedures, (A) anti-SMN 4F11 antibody 1:1000 Dilution, (B) Pierce PA5-27309 a-SMN antibody 1:1,000 dilution (C) LSBio C138149 a-SMN antibody 1:1,000 dilution In each experiment, various antibodies that recognize the hSMN-1 protein were used. One microgram of N mRNA was transfected using Lipofectamine 2000®. ~1×10 6 The cells were transfected with OptiMem® ) and harvested after 16-18 hours of transfection. Cell lysates were harvested and processed. The gel was then loaded onto an 8–16% Tris-glycine gel. The sections were then transferred to a 500-ml plate using a 500-ml PBS and treated with primary antibodies. Goat anti-mouse HRP antibody was incubated at room temperature for 45 The secondary antibody was diluted at 1:10,000 for 1 min, then washed and measured. The data showed that each antibody tested did not show any cross-reactive signal in untreated BHK cells. As shown by the above, the signal was strong for hSMN-1 and was specific for human SMN. This shows that (Figure 1). In situ hybridization (ISH) analysis
[0175] Each representative sample of biological tissue was subjected to two different in situ hybridization methods. The first approach was to measure hSMN-1 mRNA in In situ hybridization was performed using RNAscope® (Advanced The assay was performed using Cell Diagnostic's ZZ probe technology. The construct was based on the codon-optimized sequence of human SMN messenger RNA (SEQ ID NO:3). Briefly, the RNAscope® assay consisted of slide-mounted, Visualize single RMA molecules per cell in formalin-fixed paraffin-embedded (FFPE) tissue It is an in situ hybridization assay designed to quantify Each embedded tissue sample was pretreated according to the manufacturer's protocol and subjected to targeted The cells were incubated with a specific hSMN-1 RNA probe. The antibody was found to be specific for human SMN-1 and did not cross-react with mouse or rat SMN-1. After binding once, the hSMN-1 probe showed no reaction to the 6 consecutive cycles of binding. The cascade of signal amplifying molecules then hybridize to the cascade of signal amplifying molecules through amplification of the cascade of signals. The samples were treated with an HRP-labeled probe specific for the signal amplification cassette to obtain 3,3'- Assayed by color visualization with diaminobenzidine (DAB). Ubiquitin C A probe specific for α-SEQ ID NO:1 was used as a positive control. The stained samples were compared with tissues from vehicle-controlled treated rats or mice. , viewed under a standard bright-field microscope.
[0176] As a second approach, fully automated in situ hybridization analysis was used The assay was performed using the ica BondRx detection system. The probe was the human SMN messenger The RNA was generated based on the codon-optimized sequence (SEQ ID NO: 3). Each tissue sample was pretreated according to the manufacturer's protocol to detect the target protein. The cells were incubated with a specific HRP-labeled hSMN-1 RNA probe. The probe was used as a positive control (Figure 18), and the DapB probe was used as a negative control probe. Fast Red, an alkaline phosphatase staining substrate, was used as a dye (Figure 17). Hybridization was assayed using Immunohistochemical analysis
[0177] Lipid nanoparticles loaded with human SMN-1 mRNA were injected intrathecally into rats. The animals were dosed with 100 mg of 10 ... The rat spinal cord tissue samples were then assayed for expression of hSMN-1 protein. Briefly, fixed tissues embedded in paraffin were processed and mounted on slides. The slides were degreased, rehydrated, and then heated in a pressure cooker with citrate buffer. Antigen retrieval was performed using various blocking buffers followed by 4F11 antibody for 1 h. Primary antibody incubation was performed overnight at 4°C using a 1:2500 dilution. The slides are washed and incubated at ambient temperature with a secondary antibody polymer. The data were then washed and developed. At 4 hours, staining for human SMN-1 protein was observed compared to untreated controls. This demonstrates the delivery of hSMN-1 mRNA to spinal cord tissue (Figure 22). Furthermore, these data support previous findings that Once delivered, the mRNA is efficiently expressed to produce the hSMN-1 protein. This indicates that. Example 3 Efficient intracellular delivery of mRNA in neurons
[0178] The data presented in this example show that hSMN-1 mRNA-loaded liposomes (lipid or polymer nanoparticles) administered intraspinally act on cells such as anterior horn cells and dorsal root ganglia. We have successfully delivered mRNA intracellularly to neurons in the brain and spinal cord, including those that are difficult to reach. This indicates that
[0179] These results suggest that mRNA encapsulated in lipid nanoparticles induces various neuroprotective effects in the CNS following spinal administration. The results show that the 13 disclosed in Table 6 can be efficiently delivered to the cell tissues. By using different preparations of mRNA, two independent in situ hybridization As evidenced by the ELISA assay, various neurons in the spinal cord (Figures 2A-14C ) and was internalized efficiently. Surprisingly, Intracellular mRNA delivery was demonstrated in the spinal cord at a neuronal site in the difficult-to-reach ventral horn, where The protein was expressed in mouse or rat SMN-1 (Figs. 19-22). There was little or no background observed in the human SMN-1 probe. The positive SMN signals were compared with those of untreated controls (Figs. 15-17). The stained samples were compared with tissues from rats or mice treated with IgG and vehicle control. , viewed under a standard bright-field microscope.
[0180] These data suggest that the mRNA delivery strategy described herein, either lipid or nano, The nanoparticles successfully cross the complex and dense cell membranes of spinal cord neurons, and Deliver the mRNA payload for production of the encoded protein within the neuron This shows that it is possible to deliver mRNA to cells using the mRNA delivery techniques described herein. The passage of difficult-to-act neurons such as anterior horn cells and dorsal root ganglia was also successful. It is particularly surprising that the data presented here thus support the idea that mRNA delivery Lipid or polymer nanoparticles based on the delivery method are promising options for the treatment of CNS diseases In particular, the present invention provides nanoparticles loaded with hSMN mRNA. However, the researchers are investigating whether the SMN protein can be produced and whether it can be used to stimulate motor neurons in the spinal cord for the treatment of spinal muscular atrophy. These results demonstrate that drugs can be efficiently delivered to neurons, including those that are difficult to reach. Example 4 Efficient intracellular delivery of mRNA within grey and white matter of the brain
[0181] The data presented in this example demonstrate that hSMN-1 mRNA-loaded liposomes (e.g. Intraspinal administration of nanoparticles (e.g., lipid or polymer-based nanoparticles) has been shown to target the brain's vascular system, which is located deep within the brain, such as in the white matter. They have successfully delivered mRNA intracellularly to neurons in the brain, including recalcitrant tissues. , which shows that.
[0182] This study used the methods and techniques described above to study mice that were approximately 6-8 weeks of age at the start of each experiment. This study was performed in rats. Briefly, at the start of the experiment, each animal was administered isoflurane by inhalation. Once anesthetized, the exact injection site ( The hair on the upper and lower extremities (L4–L5 or L5–L6) was shaved. Following the insertion of the needle, reflex A flick of the tail was used to demonstrate puncture of the dura and to confirm intrathecal placement. Each animal received a single bolus intrathecal injection of one of the test formulations listed in Table 6. All animals were sacrificed 30 min after injection for 24 h and perfused with saline. The data presented in Example 4 describes the results of mRNA delivery using formulation 13 in Table 6 above. do. In situ hybridization (ISH) analysis
[0183] Lipid nanoparticles loaded with human SMN-1 mRNA were injected intrathecally into rats. and tissue samples were collected at 30 min and 24 h after dosing, as described above. RNAscope (registered trademark) (Advanced Cell Diagnostics) ) treated with hSMN-1 mRNA and assayed using ZZ probe technology. Each tissue sample was pretreated according to the manufacturer's protocol to detect the specific target protein. The data were analyzed using a specific hSMN-1 RNA probe. Just 30 minutes after spinal administration of RNA, the brain tissue showed increased Staining was observed everywhere, confirming previous findings and demonstrating the speed and efficacy of the mRNA delivery method. This method delivers mRNA in just 30 minutes after IT delivery. These data indicate that delivery of mRNA by the present invention is effective in targeting gray matter tissue (located in the periphery of the brain). ) and white matter tissue (located deep within the brain). This is a surprising and unexpected finding. A condition that develops as a result of dysregulation of cells located deep within the white matter tissue, which is difficult to access, and is thought to be caused by neurodegenerative disorders such as may serve as a viable therapy for treating neuromuscular disorders. Equivalent
[0184] Those of ordinary skill in the art will be able to, using routine experimentation, identify specific embodiments of the invention described herein. Many equivalents may be used to realize or ascertain the scope of the invention as defined by the preceding description. Rather, it is as set forth in the following claims, without limitation.
Claims
1. 1. A composition for use in a method of delivery of messenger RNA (mRNA) to the central nervous system (CNS), the composition comprising mRNA encoding a protein encapsulated within a liposome, such that administration of the composition results in intracellular delivery of the mRNA in neurons in the brain and / or spinal cord, the method comprising intrathecal administration of the composition to a subject in need thereof; Intracellular delivery of the mRNA results in expression of the protein encoded by the mRNA; and wherein the liposome comprises a cationic lipid, a non-cationic lipid, a cholesterol-based lipid and a PEG-modified lipid, wherein the cationic lipid is represented by formula I-g: 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, wherein each R L is independently: (i) C 8-12 alkyl, (ii) n-C 8-12 alkyl, (iii) C 9-11 alkyl, (iv) n-C 9-11 alkyl, (v) C 10 alkyl, or (vi) n-C 10 alkyl; composition.
2. a) the neurons in the brain and / or spinal cord include motor neurons in the spinal cord; or b) the neurons in the brain and / or spinal cord are selected from the group consisting of oligodendrocytes, oligodendroglial cells, astrocytes, glial cells, and combinations thereof; Optionally, the neurons in the brain and / or spinal cord include spinal cord anterior horn cells and dorsal root ganglia. A composition for use according to claim 1.
3. 3. The composition for use according to claim 1 or 2, wherein the liposome comprises one or more cationic lipids, one or more neutral lipids, one or more cholesterol-based lipids, and one or more PEG-modified lipids.
4. The one or more non-cationic lipids may be selected from the group consisting of DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DOPE (1,2-dioleyl-sn-glycero-3-phosphoethanolamine), DOPC (1,2-dioleyl-sn-glycero-3-phosphatidylcholine), DPPE (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine), DMPE (1,2-dimyristoyl-sn 4. A composition for use according to any one of claims 1 to 3, wherein the one or more non-cationic lipids are selected from: diacylglycerol, ceramide, cephalin, cerebroside, diacylglycerol, POPC, DOPG, DPPG, POPC, POPE, DSPE, SOPE and sphingomyelin, optionally wherein the one or more non-cationic lipids comprise sphingomyelin.
5. The one or more PEG-modified lipids are DMG-PEG, C8-PEG, DOG PEG, ceramide PEG, DSPE-PEG, and combinations thereof, and optionally a) the one or more PEG-modified lipids constitute 1-10% by molar ratio of the total lipid composition; or b) the one or more PEG-modified lipids constitute 5% by molar ratio of the total lipid composition; A composition for use according to any one of claims 1 to 4.
6. a) the one or more cholesterol-based lipids are selected from cholesterol, or PEGylated cholesterol; b) the liposomes have a size in the range of 40 to 100 nm; c) the mRNA has a length of 0.5 kb, 1 kb, 1.5 kb, 2 kb, 2.5 kb, 3 kb, 3.5 kb, 4 kb, 4.5 kb, or 5 kb or more; d) the protein encoded by the mRNA normally functions in the neuron in the brain and / or spinal cord; e) the protein encoded by the mRNA normally functions in a motor neuron in the spinal cord; f) the protein encoded by the mRNA is survival motor neuron (SMN) protein; and / or g) the mRNA is codon-optimized, optionally wherein the codon-optimized mRNA comprises SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:10 or SEQ ID NO:11, or wherein the codon-optimized mRNA comprises SEQ ID NO:3 or SEQ ID NO:4, and further optionally wherein the mRNA comprises the 5'UTR sequence of SEQ ID NO:7, or wherein the mRNA comprises the 3'UTR sequence of SEQ ID NO:8 or SEQ ID NO:9; h) the mRNA comprises a cap structure, and optionally A) the cap structure is selected from a cap 0, cap 1, or cap 2 structure; or B) the cap structure is an anti-reverse cap analog (ARCA) or a modified ARCA; A composition for use according to any one of claims 1 to 5.
7. A composition for use according to any one of claims 1 to 6, wherein the protein encoded by the mRNA is an enzyme, optionally wherein the enzyme is a lysosomal enzyme.
8. a) intracellular delivery of the mRNA results in intracellular expression of the protein encoded by the mRNA in the cytosol of the neuron; b) intracellular delivery of the mRNA results in intracellular expression of the protein encoded by the mRNA and subsequent secretion outside the cell from the neuron; c) the mRNA is unmodified; d) the mRNA comprises one or more modified nucleotides, optionally wherein the one or more modified nucleotides comprise pseudouridine, 2-aminoadenosine, 2-thiouridine, inosine, pyrrolo-pyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, N-1-methylpseudouridine, and / or 2-thiocytidine; e) the mRNA is delivered in an amount ranging from 0.01 mg to 10 mg per kg of body weight; f) the mRNA is delivered without eliciting substantial toxicity or immune response; and / or g) the subject is deficient in the protein encoded by the mRNA in the CNS; A composition for use according to any one of claims 1 to 7.
9. A composition for use according to any one of claims 1 to 8 for use in a method for treating a disease, disorder or abnormality associated with a deficiency of a protein in the central nervous system (CNS) in which the messenger RNA (mRNA) codes for a deficient protein, said method comprising delivering said composition to the CNS.
10. 10. A composition for use according to any one of claims 1 to 9 for use in a method for treating spinal muscular atrophy, wherein the mRNA encodes a survival motor neuron (SMN) protein and is encapsulated within the liposome, such that administration of the composition results in intracellular delivery of the mRNA in neurons in the brain and / or spinal cord, the method comprising intrathecal administration of the composition to a subject in need of treatment, and optionally a) the neurons in the brain and / or spinal cord include motor neurons in the spinal cord; b) the neurons in the brain and / or spinal cord include spinal cord anterior horn cells and dorsal root ganglia; and / or c) the codon-optimized mRNA comprises SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:10 or SEQ ID NO:11; Composition for use.
11. The codon-optimized mRNA comprises SEQ ID NO:3 or SEQ ID NO:4, and optionally a) the mRNA comprises the 5'UTR sequence of SEQ ID NO: 7, or b) the mRNA comprises the 3'UTR sequence of SEQ ID NO: 8 or SEQ ID NO: 9; A composition for use according to claim 10.
12. 12. The composition for use according to claim 10 or 11, wherein the one or more non-cationic lipids comprise sphingomyelin.
Citation Information
Patent Citations
Cleavable lipids
WO2012170889A1
Amino acid derivates functionalized on the n- terminal capable of forming drug incapsulating microspheres
WO2013063468A1
